question,language,translated_query,multilingual_chunks,translation_chunks,multilingual_english,translation_english,multilingual_content,translation_content,system_prompt,multilingual_response,translation_response,multilingual_time,translation_time,retrieval_time_multi,retrieval_time_trans,generation_time_multi,generation_time_trans,llm_model,use_claude
什么是胰岛素抵抗，它如何影响葡萄糖进入细胞？,chinese,What is insulin resistance and how does it affect glucose entering cells?,". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make glucose, but it also comes from the food you eat. Insulin is ahormonemade by your pancreas. Insulin helps move glucose from your bloodstream into your cells, where it can be used for energy. If you have diabetes, your body can't make insulin, can't use insulin as well as it should, or both. Too much glucose stays in your blood and doesn't reach your cells. This can cause glucose levels to get too high. Over time, high blood glucose levels can lead toserious health conditions. But you can take steps to manage your diabetes and try to prevent these health problems

Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them energy. If you have diabetes, your body doesn't make enough insulin or doesn't use insulin well. The glucose then stays in your blood and not enough goes into your cells. Over time, having too much glucose in your blood can causehealth problems. But you can take steps to manage your diabetes and try to prevent these health problems. Type 2 diabetes may be caused by a combination of factors: Type 2 diabetes usually starts with insulin resistance. This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insulin, and your blood glucose levels rise. You are at higher risk of developing type 2 diabetes if you: Many people with type 2 diabetes have no symptoms at all. If you do have them, the symptoms develop slowly over several years. They might be so mild that you do not notice them. The symptoms can include: Your health care provider will use blood tests to diagnose type 2 diabetes. The blood tests include: Treatment for type 2 diabetes involves managing your blood sugar levels. Many people are able to do this by living a healthy lifestyle. Some people may also need to take medicine: You can take steps to helppreventor delay type 2 diabetes by losing weight if you are overweight, eating fewer calories, and being more physically active

SUMMARY: What is diabetes?Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make glucose, but it also comes from the food you eat. Insulin is ahormonemade by your pancreas. Insulin helps move glucose from your bloodstream into your cells, where it can be used for energy.If you have diabetes, your body can't make insulin, can't use insulin as well as it should, or both. Too much glucose stays in your blood and doesn't reach your cells. This can cause glucose levels to get too high. Over time, high blood glucose levels can lead toserious health conditions. But you can take steps to manage your diabetes and try to prevent these health problems.What are the types of diabetes?There are different types of diabetes:Type 1 diabetes. If you have type 1 diabetes, your body makes little or no insulin",". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insulin, and your blood glucose levels rise. You are at higher risk of developing type 2 diabetes if you: Many people with type 2 diabetes have no symptoms at all. If you do have them, the symptoms develop slowly over several years. They might be so mild that you do not notice them. The symptoms can include: Your health care provider will use blood tests to diagnose type 2 diabetes. The blood tests include: Treatment for type 2 diabetes involves managing your blood sugar levels. Many people are able to do this by living a healthy lifestyle. Some people may also need to take medicine: You can take steps to helppreventor delay type 2 diabetes by losing weight if you are overweight, eating fewer calories, and being more physically active

Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin helps the glucose get into your cells to give them energy. If you have diabetes, your body doesn't make enough insulin or doesn't use insulin well. The glucose then stays in your blood and not enough goes into your cells. Over time, having too much glucose in your blood can causehealth problems. But you can take steps to manage your diabetes and try to prevent these health problems. Type 2 diabetes may be caused by a combination of factors: Type 2 diabetes usually starts with insulin resistance. This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond

Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make glucose, but it also comes from the food you eat. Insulin is ahormonemade by your pancreas. Insulin helps move glucose from your bloodstream into your cells, where it can be used for energy. If you have diabetes, your body can't make insulin, can't use insulin as well as it should, or both. Too much glucose stays in your blood and doesn't reach your cells. This can cause glucose levels to get too high. Over time, high blood glucose levels can lead toserious health conditions. But you can take steps to manage your diabetes and try to prevent these health problems

CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Glipizide primarily lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin. 12.2 Pharmacodynamics The insulinotropic response to a meal is enhanced with glipizide extended-release tablets administration in diabetic patients. The postprandial insulin and C-peptide responses continue to be enhanced after at least 6 months of treatment. In two randomized, double-blind, dose-response studies comprising a total of 347 patients, there was no significant increase in fasting insulin in all glipizide extended-release tablet-treated patients combined compared to placebo, although minor elevations were observed at some doses","Based on the medical information provided, I can answer your questions about insulin resistance:

**What is insulin resistance? **

Insulin resistance is a condition in which cells do not respond properly to insulin. In this condition, your cells don't respond properly to the effects of insulin.

**How ​​does it affect the entry of glucose into cells? **

1. **More Insulin Needed**: Because cells don’t respond to insulin properly, the body needs more insulin to help glucose get into the cells.

2. **Body’s Compensatory Response**: Initially, your body will make more insulin to try to get the cells to respond.

3. **Long-term effects**: But over time, your body can’t make enough insulin, causing blood sugar levels to rise.

4. **Glucose remains in the blood**: Due to insulin resistance, too much glucose remains in the blood and cannot fully enter cells to provide energy.

Insulin resistance is usually the initial stage of type 2 diabetes and is one of the important causes of high blood sugar levels.","Based on the provided medical information, insulin resistance is a condition in which your cells don't respond normally to insulin. Here's how it affects glucose entering cells:

**What happens in insulin resistance:**
- Your cells fail to respond properly to insulin, which is the hormone that normally helps glucose move from your bloodstream into your cells
- As a result, your body needs more insulin than usual to help the glucose enter your cells
- Initially, your body compensates by making more insulin to try to get cells to respond
- However, over time, your body can't make enough insulin to overcome this resistance, and your blood glucose levels rise

**The consequence:**
When glucose cannot enter your cells efficiently due to insulin resistance, it stays in your blood instead of being used for energy by your cells. This leads to elevated blood glucose levels, which over time can cause serious health problems.

Insulin resistance is typically the starting point for type 2 diabetes development. It's part of a progressive process where the body's ability to manage blood glucose becomes increasingly impaired.",". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to t
---
Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make gluco
---
Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin he
---
. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insu
---
SUMMARY: What is diabetes?Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your bo",". This is a condition in which your cells don't respond normally to insulin. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to t
---
. As a result, your body needs more insulin to help the glucose enter your cells. At first, your body makes more insulin to try to get cells to respond. But over time, your body can't make enough insu
---
Summary: Type 2diabetesis a disease in which your blood glucose, orblood sugar, levels are too high. Glucose is your main source of energy. It comes from the foods you eat. A hormone called insulin he
---
Summary: Diabetes, also known as diabetes mellitus, is a disease in which yourblood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make gluco
---
CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Glipizide primarily lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon func",Healthcare assistant prompt,"根据提供的医学信息，我可以回答您关于胰岛素抵抗的问题：

**什么是胰岛素抵抗？**

胰岛素抵抗是一种细胞对胰岛素反应不正常的状况。在这种情况下，您的细胞不能正常响应胰岛素的作用。

**它如何影响葡萄糖进入细胞？**

1. **需要更多胰岛素**：由于细胞对胰岛素的反应不正常，身体需要更多的胰岛素才能帮助葡萄糖进入细胞。

2. **身体的代偿反应**：起初，您的身体会制造更多的胰岛素，试图让细胞做出反应。

3. **长期影响**：但随着时间的推移，您的身体无法制造足够的胰岛素，导致血糖水平升高。

4. **葡萄糖滞留在血液中**：由于胰岛素抵抗，过多的葡萄糖留在血液中，无法充分进入细胞提供能量。

胰岛素抵抗通常是2型糖尿病的起始阶段，是导致血糖水平过高的重要原因之一。","根据所提供的医疗信息，胰岛素抵抗是指细胞对胰岛素无法正常反应的一种情况。以下是它如何影响葡萄糖进入细胞：

**胰岛素抵抗会发生什么：**
- 您的细胞无法对胰岛素做出适当反应，胰岛素是一种通常帮助葡萄糖从血液转移到细胞中的激素
- 因此，您的身体需要比平常更多的胰岛素来帮助葡萄糖进入您的细胞
- 最初，您的身体会通过制造更多胰岛素来尝试让细胞做出反应来进行补偿
- 然而，随着时间的推移，您的身体无法产生足够的胰岛素来克服这种阻力，您的血糖水平就会上升

**后果：**
当葡萄糖由于胰岛素抵抗而无法有效进入您的细胞时，它会留在您的血液中，而不是被您的细胞用作能量。这会导致血糖水平升高，随着时间的推移，可能会导致严重的健康问题。

胰岛素抵抗通常是 2 型糖尿病发展的起点。这是一个渐进过程的一部分，身体控制血糖的能力逐渐受损。",8.449970483779907,9.147297859191895,0.03426933288574219,0.6243250370025635,8.415701150894165,8.522972822189331,claude-sonnet-4-5-20250929,True
家族史如何影响心脏病的风险？,chinese,How does family history affect the risk of heart disease?,". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others

WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use

WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use",". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others

WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use

WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk. ( 5.1 ) Serious gastrointestinal (GI) adverse events which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at higher risk for GI events, especially the elderly. ( 5.2 ) Elevated liver enzymes, and rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen. ( 5.3 ) New onset or worsening of hypertension. Blood pressure should be monitored closely during treatment. ( 5.4 ) Fluid retention and edema. Should be used with caution in patients with fluid retention or heart failure. ( 5.5 ) Renal papillary necrosis and other renal injury with long-term use","Based on the medical information provided, family history has the following important effects on heart disease risk:

## The impact of family history

**An early family history of heart disease increases your risk**. Your risk is higher if you have a close relative who developed heart disease at an earlier age, including:

1. **Father or brother** was diagnosed with heart disease before age 55
2. **Mother or sister** diagnosed with heart disease before age 65

## Genetic factors

In addition to family history, **genetic factors** also play an important role:
- Research shows certain genes are linked to higher risk of certain heart diseases
- A family history of early heart disease increases your risk

## IMPORTANT NOTE

Family history is one of the **impossible risk factors**. However, if you have a family history of heart disease, you can lower your overall risk by changing other controllable risk factors (such as eating habits, exercise, smoking cessation, etc.).

If you have a family history of heart disease, it's recommended to have regular heart health checkups and discuss preventive measures with your doctor.","Based on the provided medical information, family history significantly affects heart disease risk in the following ways:

**Increased Risk with Family History:**
A family history of early heart disease raises your risk of developing heart disease. Specifically, you have a greater risk if you have a close family member who had heart disease at an early age:

- **For males in your family:** If your father or brother was diagnosed with heart disease before age 55
- **For females in your family:** If your mother or sister was diagnosed with heart disease before age 65

**Genetic Component:**
Research has shown that some genes are linked to a higher risk of certain heart diseases, which explains why heart disease can run in families.

**Important Note:**
Family history and genetics are risk factors that you **cannot change**. However, this knowledge is valuable because it can alert you to take preventive measures by addressing the risk factors you *can* control, such as lifestyle habits, diet, physical activity, and managing other medical conditions.

If you have a family history of early heart disease, it's particularly important to work with your healthcare provider to monitor your heart health and implement preventive strategies.",". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women
---
WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may 
---
WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may ",". Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women
---
WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may 
---
WARNINGS AND CAUTIONS: WARNINGS AND PRECAUTIONS Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may ",Healthcare assistant prompt,"根据提供的医疗信息，家族史对心脏病风险有以下重要影响：

## 家族史的影响

**早期心脏病家族史会增加您的风险**。如果您有近亲在较早年龄患心脏病，您的风险会更高，具体包括：

1. **父亲或兄弟**在55岁之前被诊断患有心脏病
2. **母亲或姐妹**在65岁之前被诊断患有心脏病

## 遗传因素

除了家族史，**遗传因素**也起重要作用：
- 研究表明某些基因与某些心脏病的高风险相关
- 早期心脏病的家族史会提高您患病的风险

## 重要提示

家族史是**无法改变的风险因素**之一。但是，如果您有心脏病家族史，您可以通过改变其他可控的风险因素（如饮食习惯、运动、戒烟等）来降低整体风险。

如果您有心脏病家族史，建议定期进行心脏健康检查，并与医生讨论预防措施。","根据提供的医疗信息，家族史通过以下方式显着影响心脏病风险：

**家族史增加风险：**
早期心脏病家族史会增加患心脏病的风险。具体来说，如果您有一位亲密的家庭成员在很小的时候就患有心脏病，那么您面临的风险会更大：

- **对于您家中的男性：** 如果您的父亲或兄弟在 55 岁之前被诊断出患有心脏病
- **对于您家庭中的女性：** 如果您的母亲或姐妹在 65 岁之前被诊断出患有心脏病

**遗传成分：**
研究表明，某些基因与某些心脏病的较高风险有关，这解释了为什么心脏病会在家族中遗传。

**重要提示：**
家族史和遗传学是您**无法改变**的风险因素。然而，这些知识很有价值，因为它可以提醒您采取预防措施，解决您“可以”控制的风险因素，例如生活习惯、饮食、身体活动和管理其他医疗状况。

如果您有早期心脏病家族史，与您的医疗保健提供者合作监测您的心脏健康并实施预防策略尤为重要。",8.810224533081055,9.110390663146973,0.03140377998352051,0.5297534465789795,8.778820753097534,8.580637216567993,claude-sonnet-4-5-20250929,True
吸烟对血压和心脏病风险有何影响？,chinese,How does smoking affect blood pressure and heart disease risk?,". Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. It may include only the lifestyle changes. These changes, such as heart-healthy eating and exercise, can be very effective. But sometimes the changes do not control or lower your high blood pressure. Then you may need to take medicine. There are different types of blood pressure medicines. Some people need to take more than one type. If your high blood pressure is caused by another medical condition or medicine, treating that condition or stopping the medicine may lower your blood pressure. NIH: National Heart, Lung, and Blood Institute

. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. It may include only the lifestyle changes. These changes, such as heart-healthy eating and exercise, can be very effective. But sometimes the changes do not control or lower your high blood pressure. Then you may need to take medicine. There are different types of blood pressure medicines. Some people need to take more than one type. If your high blood pressure is caused by another medical condition or medicine, treating that condition or stopping the medicine may lower your blood pressure. NIH: National Heart, Lung, and Blood Institute

. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy","According to the medical information provided, smoking has the following important effects on blood pressure and heart disease risk:

## Dangers of smoking:

1. **Raises Blood Pressure**: Smoking raises your blood pressure

2. **Increased risk of cardiovascular events**: Smoking puts you at a higher risk of heart attack and stroke

3. **Overall Heart Health Threats**: Smoking is a significant risk factor for heart disease

## Benefits of quitting smoking:

- **REDUCED RISK OF HEART DISEASE**: Quitting smoking can lower your risk of heart disease
- **Improve overall health**: Smoking cessation is an important component of comprehensive cardiovascular risk management

## Medical Advice:

- If you don't smoke, don't start smoking
- If you smoke, it is very important to quit smoking
- You can talk to your healthcare provider about the best way to quit smoking for you

In summary, smoking raises blood pressure and significantly increases the risk of heart disease and stroke, and quitting smoking is one of the key measures to protect cardiovascular health.","Based on the provided medical information, smoking has significant negative effects on blood pressure and heart disease risk:

**Effects on Blood Pressure:**
Cigarette smoking raises your blood pressure, which is a direct cardiovascular risk factor.

**Effects on Heart Disease Risk:**
Smoking puts you at higher risk of:
- Heart attack
- Stroke

**Recommendations:**
The medical guidance is clear:
- If you do not smoke, don't start
- If you do smoke, quitting will lower your risk of heart disease
- You should talk with your healthcare provider for help in finding the best way to quit

**Additional Context:**
Smoking is identified as one of the harmful ways people cope with stress, and stress itself is linked to heart disease in multiple ways. The combination of stress and smoking creates compounded cardiovascular risks.

Smoking cessation is specifically mentioned as an important component of comprehensive cardiovascular risk management, alongside other measures like blood pressure control, lipid control, diabetes management, exercise, and limited sodium intake.",". Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. It may include only the lifestyle changes. These changes, such as heart-healthy eating and exercise, can be very effective. But sometimes the changes do not control or lower your high blood pressure
---
. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe h",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. It may include only the lifestyle changes. These changes, such as heart-healthy eating and exercise, can be very effective. But sometimes the changes do not control or lower your high blood pressure
---
. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe h",Healthcare assistant prompt,"根据提供的医学信息，吸烟对血压和心脏病风险有以下重要影响：

## 吸烟的危害：

1. **升高血压**：吸烟会使您的血压升高

2. **增加心血管事件风险**：吸烟会使您面临更高的心脏病发作和中风风险

3. **整体心脏健康威胁**：吸烟是心脏病的重要危险因素

## 戒烟的益处：

- **降低心脏病风险**：戒烟可以降低您患心脏病的风险
- **改善整体健康**：戒烟是综合心血管风险管理的重要组成部分

## 医疗建议：

- 如果您不吸烟，请不要开始吸烟
- 如果您吸烟，戒烟是非常重要的
- 您可以咨询医疗保健提供者，寻求最适合您的戒烟方法

总之，吸烟会升高血压并显著增加心脏病和中风的风险，而戒烟则是保护心血管健康的关键措施之一。","根据提供的医学信息，吸烟对血压和心脏病风险有显着的负面影响：

**对血压的影响：**
吸烟会导致血压升高，这是一个直接的心血管危险因素。

**对心脏病风险的影响：**
吸烟会使您面临更高的风险：
- 心脏病发作
- 中风

**建议：**
医学指导很明确：
- 如果您不吸烟，请不要开始
- 如果您吸烟，戒烟会降低患心脏病的风险
- 您应该与您的医疗保健提供者交谈以寻求帮助，以找到最佳的戒烟方法

**附加上下文：**
吸烟被认为是人们应对压力的有害方式之一，而压力本身与心脏病有多种联系。压力和吸烟的结合会造成复杂的心血管风险。

戒烟被特别提到是全面心血管风险管理的重要组成部分，与血压控制、血脂控制、糖尿病管理、运动和限制钠摄入量等其他措施并列。",8.52775239944458,9.21367859840393,0.028645753860473633,0.537858247756958,8.499106645584106,8.675820350646973,claude-sonnet-4-5-20250929,True
可以改变的心脏病风险因素有哪些？,chinese,What are the risk factors for heart disease that can be modified?,". The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

ADVERSE REACTIONS: ADVERSE REACTIONS Cardiovascular Effects Tachycardia, hypotension, and hypertension have been reported. QT prolongation and/or ventricular arrhythmias have also been reported, in addition to ECG pattern changes compatible with the polymorphous configuration of Torsades de pointes, and may occur more frequently with high doses and in predisposed patients (see WARNINGS and PRECAUTIONS ). Cases of sudden and unexpected death have been reported in association with the administration of haloperidol. The nature of the evidence makes it impossible to determine definitively what role, if any, haloperidol played in the outcome of the reported cases. The possibility that haloperidol caused death cannot, of course, be excluded, but it is to be kept in mind that sudden and unexpected death may occur in psychotic patients when they go untreated or when they are treated with other antipsychotic drugs

ADVERSE REACTIONS: ADVERSE REACTIONS Cardiovascular Effects Tachycardia, hypotension, and hypertension have been reported. QT prolongation and/or ventricular arrhythmias have also been reported, in addition to ECG pattern changes compatible with the polymorphous configuration of Torsades de pointes, and may occur more frequently with high doses and in predisposed patients (see WARNINGS and PRECAUTIONS ). Cases of sudden and unexpected death have been reported in association with the administration of haloperidol. The nature of the evidence makes it impossible to determine definitively what role, if any, haloperidol played in the outcome of the reported cases. The possibility that haloperidol caused death cannot, of course, be excluded, but it is to be kept in mind that sudden and unexpected death may occur in psychotic patients when they go untreated or when they are treated with other antipsychotic drugs

ADVERSE REACTIONS: ADVERSE REACTIONS Cardiovascular Effects Tachycardia, hypotension, and hypertension have been reported. QT prolongation and/or ventricular arrhythmias have also been reported, in addition to ECG pattern changes compatible with the polymorphous configuration of Torsades de pointes, and may occur more frequently with high doses and in predisposed patients (see WARNINGS and PRECAUTIONS ). Cases of sudden and unexpected death have been reported in association with the administration of haloperidol. The nature of the evidence makes it impossible to determine definitively what role, if any, haloperidol played in the outcome of the reported cases. The possibility that haloperidol caused death cannot, of course, be excluded, but it is to be kept in mind that sudden and unexpected death may occur in psychotic patients when they go untreated or when they are treated with other antipsychotic drugs",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have

. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain heart diseases by makingheart-healthy lifestyle changesand managing any other medical conditions you have.NIH: National Heart, Lung, and Blood Institute

evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases","Based on the medical information provided, **modifiable risk factors for heart disease** include the following lifestyle habits:

1. **Eating Habits** - Reduce intake of high saturated fats, refined carbohydrates and salt

2. **Physical Activity** - Increase physical activity and avoid sitting for long periods of time

3. **Drinking** - Reduce excessive drinking

4. **Smoking** - Quit smoking and avoid exposure to secondhand smoke

5. **Stress Management** - Reduce excessive stress

6. **Other Disease Management** - Managing other medical conditions that may increase the risk of heart disease

These are all factors you can make to reduce your risk of heart disease by making lifestyle changes. In contrast, factors such as age, gender, family history/genetic factors, and racial/ethnic background cannot be changed.","Based on the provided context, the modifiable risk factors for heart disease include:

**Lifestyle Habits:**
1. **Diet** - Eating a diet high in saturated fats, refined carbohydrates, and salt
2. **Physical Activity** - Not getting enough physical activity
3. **Alcohol Consumption** - Drinking too much alcohol
4. **Smoking** - Smoking and exposure to secondhand smoke
5. **Stress** - Too much stress

**Medical Conditions:**
The context also mentions that ""having other medical conditions can raise your risk of heart diseases,"" which can often be managed through treatment. Specific modifiable medical risk factors mentioned include:
- Hypertension (high blood pressure)
- Low HDL-C (low ""good"" cholesterol)
- High cholesterol levels
- Type 2 diabetes (with proper management)
- Elevated triglyceride levels

These are all factors that can be changed or managed through heart-healthy lifestyle changes, medications, and medical treatment to lower the risk of developing heart disease.",". The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
ADVERSE REACTIONS: ADVERSE REACTIONS Cardiovascular Effects Tachycardia, hypotension, and hypertension have been reported. QT prolongation and/or ventricular arrhythmias have also been reported, in ad
---
ADVERSE REACTIONS: ADVERSE REACTIONS Cardiovascular Effects Tachycardia, hypotension, and hypertension have been reported. QT prolongation and/or ventricular arrhythmias have also been reported, in ad
---
ADVERSE REACTIONS: ADVERSE REACTIONS Cardiovascular Effects Tachycardia, hypotension, and hypertension have been reported. QT prolongation and/or ventricular arrhythmias have also been reported, in ad",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make
---
. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain hear
---
evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for reva
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami",Healthcare assistant prompt,"根据提供的医疗信息，**可以改变的心脏病风险因素**包括以下生活方式习惯：

1. **饮食习惯** - 减少高饱和脂肪、精制碳水化合物和盐分的摄入

2. **体育活动** - 增加身体活动量，避免久坐不动

3. **饮酒** - 减少过量饮酒

4. **吸烟** - 戒烟并避免接触二手烟

5. **压力管理** - 减少过度压力

6. **其他疾病管理** - 控制其他可能增加心脏病风险的医疗状况

这些都是您可以通过改变生活方式来降低心脏病风险的因素。相比之下，年龄、性别、家族史/遗传因素和种族/民族背景等因素是无法改变的。","根据所提供的情况，心脏病的可改变危险因素包括：

**生活习惯：**
1. **饮食** - 饮食富含饱和脂肪、精制碳水化合物和盐
2. **体力活动** - 没有进行足够的体力活动
3. **酒精消耗** - 饮酒过多
4. **吸烟** - 吸烟和接触二手烟
5. **压力** - 压力太大

**医疗状况：**
上下文还提到“患有其他疾病会增加患心脏病的风险”，这通常可以通过治疗来控制。提到的具体可改变的医疗风险因素包括：
- 高血压（高血压）
- 低 HDL-C（低“好”胆固醇）
- 高胆固醇水平
- 2 型糖尿病（适当管理）
- 甘油三酯水平升高

这些因素都可以通过有利于心脏健康的生活方式的改变、药物和医疗来改变或管理，以降低患心脏病的风险。",7.4590253829956055,8.608112335205078,0.03417015075683594,0.5500130653381348,7.4248552322387695,8.058099269866943,claude-sonnet-4-5-20250929,True
不同族群之间心脏病发病率有什么差异？,chinese,What are the differences in heart disease rates among different ethnic groups?,". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have

. The subjects included in the study were men aged 35 to 59 with serum cholesterol levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be extrapolated to females and other segments of the hypercholesterolemic population. (See also PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility .) Two controlled clinical trials have examined the effects of cholestyramine monotherapy upon coronary atherosclerotic lesions using coronary arteriography. In the NHLBI Type II Coronary Intervention Trial 2 , 116 patients (80% male) with coronary artery disease (CAD) documented by arteriography were randomized to cholestyramine resin or placebo for five years of treatment. Final study arteriography revealed progression of coronary artery disease in 49% of placebo patients compared to 32% of the cholestyramine resin group (p<0.05). In the St

Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cause of death in the United States, but there are ways to prevent and manage many types of heart disease. There are many different types of heart disease. Some you may be born with, calledcongenital heart disease. Other types develop during your lifetime. Coronary artery disease(also called coronary heart disease) is the most common type of heart disease. It happens slowly over time when a sticky substance called plaque builds up in the arteries that supply your heart muscle with blood. The plaque narrows or blocks blood flow to the heart muscle and can lead to other heart problems: Other types of heart diseases may affect yourheart valvesor heart muscle (cardiomyopathy). The causes of heart disease depend on the type of disease",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cause of death in the United States, but there are ways to prevent and manage many types of heart disease. There are many different types of heart disease. Some you may be born with, calledcongenital heart disease. Other types develop during your lifetime. Coronary artery disease(also called coronary heart disease) is the most common type of heart disease. It happens slowly over time when a sticky substance called plaque builds up in the arteries that supply your heart muscle with blood. The plaque narrows or blocks blood flow to the heart muscle and can lead to other heart problems: Other types of heart diseases may affect yourheart valvesor heart muscle (cardiomyopathy). The causes of heart disease depend on the type of disease

. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make you more likely to develop heart disease. Some of these factors you can change, but others you cannot. Your symptoms will depend on the type of heart disease you have. You may not have symptoms at first. In some cases, you may not know you have heart disease until you have a complication such as a heart attack. To find out if you have heart disease, your health care provider will: In some cases, your provider may refer you to a cardiologist (a doctor who specializes in heart diseases) for tests, diagnosis, and care. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others","According to the medical information provided, there are the following differences in the incidence of heart disease between different ethnic groups:

1. **African Americans**: More likely to die from heart disease than white people

2. **Hispanics**: Less likely to die from heart disease than whites

3. **Asian Americans**:
   - The overall incidence of heart disease is lower than other ethnic groups
   - But South Asian Americans have higher rates of heart disease

4. **High-risk groups**:
   - black man
   - white people
   - American Indian/Alaska Native
   These groups have higher risk of heart disease than other groups

Overall, heart disease is the leading cause of death among most racial and ethnic groups in the United States, but significant incidence differences do exist between groups.","Based on the provided context, here are the key differences in heart disease rates among different ethnic groups:

**Higher Risk Groups:**
- **African Americans**: More likely than Whites to die of heart disease
- **Black people**: Listed as one of the groups with higher risks
- **White people**: Also identified as having higher risks
- **American Indian/Alaska Native people**: Have higher risks compared to other groups
- **South Asian Americans**: Have higher rates of heart disease compared to other Asian American subgroups

**Lower Risk Groups:**
- **Hispanic Americans**: Less likely to die of heart disease compared to other groups
- **Asian Americans**: As a group, have lower rates of heart disease than other groups (though South Asian Americans are an exception)

**Important Note:**
While heart disease is the leading cause of death in most racial and ethnic groups in the United States, the rates and risks vary significantly among different populations. These differences may be influenced by various factors including genetics, lifestyle habits, access to healthcare, and other social determinants of health.",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make
---
. The subjects included in the study were men aged 35 to 59 with serum cholesterol levels above 265 mg/dL and no previous history of heart disease. It is not clear to what extent these findings can be
---
Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cau",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cau
---
. The causes of heart disease depend on the type of disease. Some possible causes include lifestyle, genetics, infections, medicines, and other diseases. There are many different factors that can make
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women",Healthcare assistant prompt,"根据提供的医疗信息，不同族群之间心脏病发病率存在以下差异：

1. **非裔美国人**：比白人更容易死于心脏病

2. **西班牙裔美国人**：死于心脏病的可能性低于白人

3. **亚裔美国人**：
   - 整体上心脏病发病率低于其他族群
   - 但南亚裔美国人的心脏病发病率较高

4. **高风险族群**：
   - 黑人
   - 白人
   - 美国印第安人/阿拉斯加原住民
   这些族群的心脏病风险高于其他族群

总体而言，心脏病是美国大多数种族和族裔群体的主要死因，但不同族群之间确实存在显著的发病率差异。","根据所提供的背景，以下是不同种族之间心脏病发病率的主要差异：

**高风险群体：**
- **非裔美国人**：比白人更有可能死于心脏病
- **黑人**：被列为风险较高的群体之一
- **白人**：也被认为具有更高的风险
- **美洲印第安人/阿拉斯加原住民**：与其他群体相比具有更高的风险
- **南亚裔美国人**：与其他亚裔美国人亚群体相比，心脏病发病率更高

**低风险群体：**
- **西班牙裔美国人**：与其他群体相比，死于心脏病的可能性较小
- **亚裔美国人**：作为一个群体，心脏病的发病率低于其他群体（尽管南亚裔美国人是一个例外）

**重要提示：**
虽然心脏病是美国大多数种族和族裔群体的首要死因，但不同人群的发病率和风险差异很大。这些差异可能受到多种因素的影响，包括遗传、生活习惯、医疗保健和其他健康社会决定因素。",6.781769275665283,8.785884618759155,0.04539752006530762,0.5116486549377441,6.736371755599976,8.274235963821411,claude-sonnet-4-5-20250929,True
酒精摄入对心脏病风险有什么影响？,chinese,What effect does alcohol consumption have on heart disease risk?,". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property","According to the medical information provided, the content mainly related to safety warnings for the drug varenicline and did not directly address the general impact of alcohol intake on the risk of heart disease.

However, relevant information mentioned in the article includes:

1. **Alcohol-Drug Interaction**: Patients taking varenicline may have enhanced effects of alcohol after drinking alcohol. Patients are advised to reduce their alcohol intake until they understand how the drug affects them.

2. **Risk of cardiovascular events**: Patients with underlying cardiovascular disease may be at higher risk for cardiovascular events, but this needs to be balanced against the health benefits of quitting smoking. Patients should notify their medical provider of any new or worsening cardiovascular symptoms and seek immediate medical attention if they develop symptoms of myocardial infarction or stroke.

**Summary**: The information provided does not address the general effects of alcohol consumption on heart disease risk, only considerations during use of specific medications.","Based on the provided medical context, there is no information about the effect of alcohol consumption on heart disease risk. 

The context only discusses varenicline (a smoking cessation medication) and mentions that:
- Increased effects of alcohol have been reported when taking varenicline
- Patients should reduce alcohol consumption until they know how varenicline affects them
- Patients with underlying cardiovascular disease may be at increased risk of cardiovascular events while taking varenicline

The information does not address the general relationship between alcohol consumption and heart disease risk outside the context of varenicline use.",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",". ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",Healthcare assistant prompt,"根据提供的医疗信息，内容主要涉及伐尼克兰(varenicline)药物的安全警告，并未直接说明酒精摄入对心脏病风险的一般性影响。

不过，文中提到的相关信息包括：

1. **酒精与药物相互作用**：服用伐尼克兰的患者饮酒后可能会增强酒精的效应，建议患者在了解药物如何影响自己之前减少酒精摄入量。

2. **心血管事件风险**：患有潜在心血管疾病的患者可能面临更高的心血管事件风险，但这需要与戒烟的健康益处相平衡。患者应通知医疗提供者任何新出现或恶化的心血管症状，如出现心肌梗死或中风的症状应立即就医。

**总结**：提供的信息未包含关于酒精摄入对心脏病风险一般性影响的内容，仅涉及特定药物使用期间的注意事项。","根据所提供的医学背景，没有关于饮酒对心脏病风险影响的信息。 

上下文仅讨论伐尼克兰（一种戒烟药物）并提到：
- 据报道，服用伐尼克兰时酒精的影响会增加
- 患者应减少饮酒，直到他们知道伐尼克兰对他们有何影响
- 患有潜在心血管疾病的患者服用伐尼克兰时发生心血管事件的风险可能会增加

该信息并未涉及伐尼克兰使用范围之外的饮酒与心脏病风险之间的一般关系。",9.074731826782227,7.177610397338867,0.030222177505493164,0.5794603824615479,9.044509649276733,6.598150014877319,claude-sonnet-4-5-20250929,True
额外的卡路里对心脏病风险有什么影响？,chinese,What impact do extra calories have on heart disease risk?,". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan lower these risks.Eating a healthy diet.Try to limit saturatedfats, foods high insodium(salt), and addedsugars. Instead, eat plenty of fresh fruit, vegetables, and whole grains. TheDASH dietis an example of an eating plan that can help you to lower your blood pressure and cholesterol, two things that can lower your risk of heart disease.Getting regular physical activity.Regular physical activity has many benefits, including strengthening your heart and improving your circulation. It can also help you maintain a healthy weight and lower cholesterol and blood pressure. All of these can lower your risk of heart disease.Limitingalcohol.Drinking too much alcohol can raise your blood pressure. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease

WARNINGS: WARNINGS SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups ( Diabetes , 19, supp. 2:747-830, 1970). UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2½ times that of patients treated with diet alone

. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk. Olanzapine's specific metabolic profile is presented below. Hyperglycemia and Diabetes Mellitus Healthcare providers should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus, or having borderline increased blood glucose level (fasting 100 mg/dL to 126 mg/dL, nonfasting 140 mg/dL to 200 mg/dL). Patients taking olanzapine should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing

. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk. Olanzapine's specific metabolic profile is presented below. Hyperglycemia and Diabetes Mellitus Healthcare providers should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus, or having borderline increased blood glucose level (fasting 100 mg/dL to 126 mg/dL, nonfasting 140 mg/dL to 200 mg/dL). Patients taking olanzapine should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan lower these risks.Eating a healthy diet.Try to limit saturatedfats, foods high insodium(salt), and addedsugars. Instead, eat plenty of fresh fruit, vegetables, and whole grains. TheDASH dietis an example of an eating plan that can help you to lower your blood pressure and cholesterol, two things that can lower your risk of heart disease.Getting regular physical activity.Regular physical activity has many benefits, including strengthening your heart and improving your circulation. It can also help you maintain a healthy weight and lower cholesterol and blood pressure. All of these can lower your risk of heart disease.Limitingalcohol.Drinking too much alcohol can raise your blood pressure. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease

. ( 5.5 ) Weight Gain: Potential consequences of weight gain should be considered. Patients should receive regular monitoring of weight. ( 5.5 ) Tardive Dyskinesia: Discontinue if clinically appropriate. ( 5.6 ) Orthostatic Hypotension: Orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, may occur especially during initial dose titration. Use caution in patients with cardiovascular disease, cerebrovascular disease, and those conditions that could affect hemodynamic responses. ( 5.7 ) Leukopenia, Neutropenia, and Agranulocytosis: Has been reported with antipsychotics, including olanzapine

. ( 5.5 ) Weight Gain: Potential consequences of weight gain should be considered. Patients should receive regular monitoring of weight. ( 5.5 ) Tardive Dyskinesia: Discontinue if clinically appropriate. ( 5.6 ) Orthostatic Hypotension: Orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, may occur especially during initial dose titration. Use caution in patients with cardiovascular disease, cerebrovascular disease, and those conditions that could affect hemodynamic responses. ( 5.7 ) Leukopenia, Neutropenia, and Agranulocytosis: Has been reported with antipsychotics, including olanzapine

. ( 5.5 ) Weight Gain: Potential consequences of weight gain should be considered. Patients should receive regular monitoring of weight. ( 5.5 ) Tardive Dyskinesia: Discontinue if clinically appropriate. ( 5.6 ) Orthostatic Hypotension: Orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, may occur especially during initial dose titration. Use caution in patients with cardiovascular disease, cerebrovascular disease, and those conditions that could affect hemodynamic responses. ( 5.7 ) Leukopenia, Neutropenia, and Agranulocytosis: Has been reported with antipsychotics, including olanzapine","According to the medical information provided, extra calories have the following effects on heart disease risk:

**Main Impact:**

1. **Causes weight gain** - Extra calories can cause weight gain

2. **Increased risk of heart disease** - Weight gain increases the risk of heart disease

**Specific mechanism:**

Extra calories (especially from excessive alcohol consumption) can:
- Increased blood pressure
- Causes weight gain
- Both increase the risk of heart disease

**Prevention Advice:**

- Controlling your weight can reduce risk factors related to heart disease, including:
  - high cholesterol
  - High triglyceride levels
  - high blood pressure
  - Diabetes

- It is recommended to adopt a healthy diet and limit:
  - Saturated fat
  - Foods high in sodium (salt)
  - Added sugar

- Eat more fresh fruits, vegetables and whole grains

Overall, extra calories significantly increase the risk of heart disease by causing weight gain and raising blood pressure.","Based on the provided context, extra calories increase heart disease risk in the following ways:

1. **Weight Gain**: Extra calories may cause weight gain, which is directly linked to increased heart disease risk.

2. **Indirect Effects Through Risk Factors**: Weight gain from excess calories is associated with:
   - High blood cholesterol levels
   - High triglyceride levels
   - High blood pressure
   - Diabetes

All of these conditions are established risk factors for heart disease.

The context specifically mentions this in relation to alcohol consumption, noting that ""drinking too much alcohol...adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease.""

The information emphasizes that controlling weight through managing calorie intake can help lower these cardiovascular risks. This is why eating a healthy diet that limits saturated fats, sodium, and added sugars while focusing on fresh fruits, vegetables, and whole grains is recommended as part of heart disease prevention.",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan low
---
WARNINGS: WARNINGS SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortalit
---
. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk. Olanzapine's specific metabolic profile is presented below. Hyperglycemia and Diabetes Mellitus Healthcare pro
---
. Metabolic changes may be associated with increased cardiovascular/cerebrovascular risk. Olanzapine's specific metabolic profile is presented below. Hyperglycemia and Diabetes Mellitus Healthcare pro",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. This is mostly because they are linked to other heart disease risk factors, including high blood cholesterol and triglyceride levels, high blood pressure, and diabetes.Controlling your weightcan low
---
. ( 5.5 ) Weight Gain: Potential consequences of weight gain should be considered. Patients should receive regular monitoring of weight. ( 5.5 ) Tardive Dyskinesia: Discontinue if clinically appropria
---
. ( 5.5 ) Weight Gain: Potential consequences of weight gain should be considered. Patients should receive regular monitoring of weight. ( 5.5 ) Tardive Dyskinesia: Discontinue if clinically appropria
---
. ( 5.5 ) Weight Gain: Potential consequences of weight gain should be considered. Patients should receive regular monitoring of weight. ( 5.5 ) Tardive Dyskinesia: Discontinue if clinically appropria",Healthcare assistant prompt,"根据提供的医疗信息，额外的卡路里对心脏病风险有以下影响：

**主要影响：**

1. **导致体重增加** - 额外的卡路里会引起体重增长

2. **增加心脏病风险** - 体重增加会提高患心脏病的风险

**具体机制：**

额外的卡路里（特别是来自过量饮酒）会：
- 升高血压
- 导致体重增加
- 这两者都会增加心脏病风险

**预防建议：**

- 控制体重可以降低心脏病相关风险因素，包括：
  - 高胆固醇
  - 高甘油三酯水平
  - 高血压
  - 糖尿病

- 建议采取健康饮食方式，限制：
  - 饱和脂肪
  - 高钠（盐）食物
  - 添加糖

- 多吃新鲜水果、蔬菜和全谷物

总之，额外的卡路里通过导致体重增加和升高血压，从而显著增加心脏病的风险。","根据所提供的背景，额外的卡路里通过以下方式增加心脏病风险：

1. **体重增加**：额外的卡路里可能会导致体重增加，这与心脏病风险增加直接相关。

2. **通过风险因素产生的间接影响**：过量卡路里导致的体重增加与以下因素相关：
   - 高血液胆固醇水平
   - 高甘油三酯水平
   - 高血压
   - 糖尿病

所有这些情况都是心脏病的既定危险因素。

上下文特别提到了与饮酒有关的这一点，并指出“喝太多酒......会增加额外的卡路里，这可能会导致体重增加。这两者都会增加患心脏病的风险。”

该信息强调，通过控制热量摄入来控制体重有助于降低这些心血管风险。这就是为什么建议采取健康饮食，限制饱和脂肪、钠和添加糖，同时注重新鲜水果、蔬菜和全谷物，作为预防心脏病的一部分。",8.856468915939331,8.140386819839478,0.03449058532714844,0.5915160179138184,8.821978330612183,7.548870801925659,claude-sonnet-4-5-20250929,True
压力与心脏病有什么关系？,chinese,What is the connection between stress and heart disease?,". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive and angina patients who have congestive heart failure controlled by digitalis and diuretics, metoprolol should be administered cautiously. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, metoprolol should be withdrawn

WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive and angina patients who have congestive heart failure controlled by digitalis and diuretics, metoprolol should be administered cautiously. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, metoprolol should be withdrawn

Summary: Blood pressure is the force of your blood pushing against the walls of your arteries. Each time your heart beats, it pumps blood into the arteries. Your blood pressure is highest when your heart beats, pumping the blood. This is called systolic pressure. When your heart is at rest, between beats, your blood pressure falls. This is called diastolic pressure. Your blood pressure reading uses these two numbers. Usually the systolic number comes before or above the diastolic number. For example, 120/80 means a systolic of 120 and a diastolic of 80. High blood pressure usually has no symptoms. So the only way to find out if you have it is to get regular blood pressure checks from your health care provider. Your provider will use a gauge, a stethoscope or electronic sensor, and a blood pressure cuff. They will take two or more readings at separate appointments before making a diagnosis

SUMMARY: What is blood pressure?Blood pressure is the force of your blood pushing against the walls of your arteries. Each time your heart beats, it pumps blood into the arteries. Your blood pressure is highest when your heart beats, pumping the blood. This is called systolic pressure. When your heart is at rest, between beats, your blood pressure falls. This is called diastolic pressure.Your blood pressure reading uses these two numbers. Usually the systolic number comes before or above the diastolic number. For example, 120/80 means a systolic of 120 and a diastolic of 80.How is high blood pressure diagnosed?High blood pressure usually has no symptoms. So the only way to find out if you have it is to get regular blood pressure checks from your health care provider. Your provider will use a gauge, a stethoscope or electronic sensor, and a blood pressure cuff",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

. Sometimeswomenwill have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks iscoronary artery disease(CAD). With CAD, there is a buildup of cholesterol and other material, called plaque, on their inner walls or the arteries. This isatherosclerosis. It can build up for years. Eventually an area of plaque can rupture (break open). Ablood clotcan form around the plaque and block the artery. A less common cause of heart attack is a severe spasm (tightening) of a coronary artery. The spasm cuts off blood flow through the artery. At the hospital, health care providers make a diagnosis based on your symptoms, blood tests, and differentheart health tests. Treatments may include medicines and medical procedures such ascoronary angioplasty. After a heart attack,cardiac rehabilitationand lifestyle changes can help you recover. NIH: National Heart, Lung, and Blood Institute

. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscle weakness, muscle spasm Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with the institution of levothyroxine therapy. Adverse Reactions in Pediatric Patients Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy

. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscle weakness, muscle spasm Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with the institution of levothyroxine therapy. Adverse Reactions in Pediatric Patients Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy

WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive and angina patients who have congestive heart failure controlled by digitalis and diuretics, metoprolol should be administered cautiously. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, metoprolol should be withdrawn","According to the medical information provided, the relationship between stress and heart disease is mainly reflected in the following aspects:

## Effects of stress on the heart:

1. **Extreme stress may trigger a heart attack**
   - Extreme stress can be a 'trigger' for heart attack

2. **Poor stress coping can harm heart health**
   Common ways to cope with stress include:
   - Overeating
   - Alcoholism
   - Smoking
   
   These methods are harmful to the heart

## Suggested stress management methods:

To protect your heart health, here are some healthy stress management practices:
- Exercise
- Listen to music
- Focus on something calm or tranquil
- Meditation

In short, stress itself can directly induce heart problems, and improper coping with stress can further increase the risk of heart disease. Therefore, learning to manage stress in healthy ways is important to prevent heart disease.","Based on the provided medical information, there is a clear connection between stress and heart disease:

**Direct Connection:**
- **Extreme stress can trigger a heart attack** - Stress acts as a direct ""trigger"" that can precipitate cardiac events in susceptible individuals.

**Indirect Connection:**
- **Unhealthy coping mechanisms** - Common ways people cope with stress are harmful to heart health, including:
  - Overeating
  - Heavy drinking
  - Smoking

These stress-related behaviors can contribute to risk factors for heart disease.

**Recommended Stress Management:**
The context suggests several healthy ways to manage stress that can benefit heart health:
- Exercise
- Listening to music
- Focusing on something calm or peaceful
- Meditating

**Related Risk Factors:**
The information also notes that inadequate sleep (which can be stress-related) increases the risk of:
- High blood pressure
- Obesity
- Diabetes

All three of these conditions subsequently raise the risk of heart disease.

In summary, stress has both a direct relationship with heart disease (as a trigger for heart attacks) and an indirect relationship through promoting unhealthy behaviors and lifestyle factors that damage cardiovascular health.",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the poten
---
WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the poten
---
Summary: Blood pressure is the force of your blood pushing against the walls of your arteries. Each time your heart beats, it pumps blood into the arteries. Your blood pressure is highest when your he
---
SUMMARY: What is blood pressure?Blood pressure is the force of your blood pushing against the walls of your arteries. Each time your heart beats, it pumps blood into the arteries. Your blood pressure ",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
. Sometimeswomenwill have different symptoms then men. For example, they are more likely to feel tired for no reason. The most common cause of heart attacks iscoronary artery disease(CAD). With CAD, t
---
. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irri
---
. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irri
---
WARNINGS: WARNINGS Hypertension and Angina Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the poten",Healthcare assistant prompt,"根据提供的医疗信息，压力与心脏病的关系主要体现在以下几个方面：

## 压力对心脏的影响：

1. **极端压力可能诱发心脏病发作**
   - 极度的压力可以成为心脏病发作的""触发因素""

2. **不良的压力应对方式会损害心脏健康**
   常见的压力应对方式如：
   - 暴饮暴食
   - 酗酒
   - 吸烟
   
   这些方式都对心脏有害

## 建议的压力管理方法：

为了保护心脏健康，可以采用以下健康的压力管理方式：
- 运动锻炼
- 听音乐
- 专注于平静或宁静的事物
- 冥想

总之，压力本身可以直接诱发心脏问题，而不当的压力应对方式会进一步增加心脏病风险。因此，学会用健康的方式管理压力对预防心脏病非常重要。","根据提供的医疗信息，压力与心脏病之间存在明显的联系：

**直接连接：**
- **极端压力可引发心脏病** - 压力作为直接“触发因素”，可促使易感人群发生心脏病。

**间接连接：**
- **不健康的应对机制** - 人们应对压力的常见方式有害心脏健康，包括：
  - 暴饮暴食
  - 大量饮酒
  - 吸烟

这些与压力相关的行为可能会导致心脏病的危险因素。

**推荐的压力管理：**
本文提出了几种有益于心脏健康的压力管理方法：
- 锻炼
- 听音乐
- 专注于平静或平和的事情
- 冥想

**相关风险因素：**
该信息还指出，睡眠不足（可能与压力有关）会增加以下风险：
- 高血压
- 肥胖
- 糖尿病

所有这三种情况都会增加患心脏病的风险。

总之，压力既与心脏病（作为心脏病发作的诱因）有直接关系，又通过促进损害心血管健康的不健康行为和生活方式因素而产生间接关系。",10.110524892807007,9.624727249145508,0.05581831932067871,0.5554063320159912,10.054706573486328,9.069320917129517,claude-sonnet-4-5-20250929,True
哪个族群的心脏病发病率比其他族群低？,chinese,Which ethnic group has lower rates of heart disease than other groups?,". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity

marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity

marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity

marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cause of death in the United States, but there are ways to prevent and manage many types of heart disease. There are many different types of heart disease. Some you may be born with, calledcongenital heart disease. Other types develop during your lifetime. Coronary artery disease(also called coronary heart disease) is the most common type of heart disease. It happens slowly over time when a sticky substance called plaque builds up in the arteries that supply your heart muscle with blood. The plaque narrows or blocks blood flow to the heart muscle and can lead to other heart problems: Other types of heart diseases may affect yourheart valvesor heart muscle (cardiomyopathy). The causes of heart disease depend on the type of disease

. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32 percent fewer first hospitalizations for heart failure, and 32 percent fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect

. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32 percent fewer first hospitalizations for heart failure, and 32 percent fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect","According to medical information provided in English, **Asian Americans as a group have lower rates of heart disease than other ethnic groups**.

But it’s important to note that the same message also states that South Asian Americans actually have higher rates of heart disease than other groups. This illustrates the differences within Asian groups.

Additionally, the information states that Hispanic Americans are less likely to die from heart disease than white people.","Based on the provided context, **Asian Americans as a group have lower rates of heart disease than other groups**. 

However, it's important to note that there is variation within this population - the context specifically mentions that South Asian Americans have higher rates of heart disease compared to other Asian American subgroups.",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing s
---
marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing s
---
marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing s
---
marketed or adverse experiences occurring in 0.5 to 1 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing s",". For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
Summary: Heart disease is a general term that includes many types of heart problems. It's a type of cardiovascular disease, which means heart and blood vessel disease. Heart disease is the leading cau
---
. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 3
---
. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 3",Healthcare assistant prompt,"根据提供的英文医疗信息，**亚裔美国人（Asian Americans）作为一个整体群体，心脏病发病率比其他族群低**。

但需要注意的是，同一段信息也指出，南亚裔美国人（South Asian Americans）的心脏病发病率实际上比其他群体更高。这说明亚裔群体内部存在差异。

此外，信息还提到西班牙裔美国人（Hispanic Americans）死于心脏病的可能性比白人低。","根据所提供的背景，**亚裔美国人作为一个群体的心脏病发病率低于其他群体**。 

然而，值得注意的是，这个人群内部存在差异——上下文特别提到，与其他亚裔美国人亚群体相比，南亚裔美国人的心脏病发病率更高。",6.702324390411377,5.446202993392944,0.026750802993774414,0.4331378936767578,6.6755735874176025,5.0130650997161865,claude-sonnet-4-5-20250929,True
家族成员心脏病诊断的年龄阈值是多少会增加风险？,chinese,What is the age threshold for heart disease diagnosis in family members that increases risk?,". 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them",". 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine headache without aura, that do not contraindicate COC use in younger females, are contraindications to use in women over 35 years of age [ see Contraindications (4) and Warnings and Precautions (5.1) ]. Consider the presence of underlying risk factors that may increase the risk of cardiovascular disease or VTE, particularly before initiating Iclevia for women over 35 years, such as: Hypertension Diabetes Dyslipidemia Obesity 5.6 Gallbladder Disease Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs, including Iclevia, may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use

. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Family history and genetics.A family history of early heart disease raises your risk. And research has shown that some genes are linked to a higher risk of certain heart diseases.Race/ethnicity.Heart disease is the leading cause of death in most racial and ethnic groups in the United States. However, certain groups have higher risks than others. This includes Black people, White people, and American Indian/Alaska Native people.Lifestyle habits.Over time, unhealthy lifestyle habits can raise your risk of heart disease. These can include:Eating a diet high in saturatedfats, refined carbohydrates, andsalt.Not gettingenough physical activity.Drinking too muchalcohol.Smokingand exposure tosecondhand smoke.Too muchstress.Having other medical conditionscan raise your risk of heart diseases

. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women some protection against heart diseaseDiabetesraises the risk of heart disease more in women than in men.Your race or ethnicity.Certain groups have higher risks than others

. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease than other groups, but South Asian Americans have higher ratesYour family history.You have a greater risk if you have a close family member who had heart disease at an early age, for example if:Your father or brother was diagnosed before age 55Your mother or sister was diagnosed before age 65What are the heart disease risk factors I can change and what can I do to lower my risk?There are many heart disease risk factors that you can change.  If you make these changes, you don't just help protect your heart. You can also improve your overall health and well-being.You may have a lot of changes to make. If you need to, you can make the changes gradually, one at a time. What's most important is that you make them","According to the medical information provided, your risk of heart disease is increased if a close family member is diagnosed with heart disease at the following ages:

**Male family members:**
- A father or brother diagnosed with heart disease before age 55

**Female family members:**
- Mother or sister diagnosed with heart disease before age 65

A family history of these premature heart diseases can significantly increase your risk of developing heart disease. If you have such a family history, it is recommended that you pay more attention to other controllable risk factors for heart disease, such as maintaining a healthy lifestyle and regular physical examinations.","Based on the provided context, the age thresholds for heart disease diagnosis in family members that increase your risk are:

- **For male family members (father or brother):** Diagnosed before age **55**
- **For female family members (mother or sister):** Diagnosed before age **65**

Having a close family member diagnosed with heart disease at these early ages indicates a greater risk for developing heart disease yourself.",". 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t",". 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. 5.5 Age-related Considerations The risk for cardiovascular disease and prevalence of risk factors for cardiovascular disease increase with age. Certain conditions, such as smoking and migraine heada
---
. Some of these factors you can change, but others you cannot.Age.Your risk of heart disease goes up as you get older.Sex.Some factors may affect heart disease risk differently inwomenthan in men.Fami
---
. The risk is higher in:Men age 45 and olderWomen age 55 and olderYour sex.Some risk factors may affect heart disease risk differently inwomenthan in men. For example:Thehormoneestrogen provides women
---
. For example:African Americans are more likely than Whites to die of heart disease, while Hispanic Americans are less likely to die of itAsian Americans as a group have lower rates of heart disease t",Healthcare assistant prompt,"根据提供的医学信息，如果您的近亲家族成员在以下年龄被诊断患有心脏病，会增加您的心脏病风险：

**男性家族成员：**
- 父亲或兄弟在55岁之前被诊断患有心脏病

**女性家族成员：**
- 母亲或姐妹在65岁之前被诊断患有心脏病

这些早发性心脏病的家族史会显著增加您患心脏病的风险。如果您有这样的家族史，建议您更加注意其他可控的心脏病风险因素，如保持健康的生活方式、定期体检等。","根据所提供的背景，家庭成员诊断心脏病的年龄阈值会增加您的风险：

- **对于男性家庭成员（父亲或兄弟）：** 在 **55 岁之前诊断**
- **对于女性家庭成员（母亲或姐妹）：** 在 **65 岁之前诊断**

亲密的家庭成员在这么小的年纪就被诊断出患有心脏病，表明您自己患心脏病的风险更大。",7.146236419677734,6.273425102233887,0.034503936767578125,0.503558874130249,7.111732482910156,5.769866228103638,claude-sonnet-4-5-20250929,True
饮酒超过推荐量对心脏病风险有什么影响？,chinese,What impact does drinking more than recommended amounts have on heart disease risk?,". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property","According to the medical information provided, drinking more than recommended amounts has the following effects on heart disease risk:

1. **Raises Blood Pressure** - Excessive alcohol consumption can increase blood pressure levels

2. **WEIGHT GAIN** - Alcohol contains extra calories that may lead to weight gain

3. **Increased risk of heart disease** - High blood pressure and weight gain are both factors that increase the risk of heart disease

**Recommended alcohol consumption:**
- Men: no more than 2 cups per day
- Women: no more than 1 cup per day

Medical advice states that it is best not to drink alcohol. If you do drink alcohol, keep it within recommended amounts to reduce your risk of heart disease.","Based on the provided medical information, drinking more than the recommended amounts has the following impacts on heart disease risk:

1. **Raises blood pressure** - Excessive alcohol consumption increases blood pressure levels

2. **Adds extra calories leading to weight gain** - Both elevated blood pressure and weight gain increase the risk of heart disease

The recommended limits to minimize these risks are:
- **Men**: No more than 2 drinks per day
- **Women**: No more than 1 drink per day

The context emphasizes that it's best not to drink at all, but if you do choose to drink, staying within these limits is important for heart health. Drinking beyond these recommended amounts directly increases your risk of developing heart disease through multiple mechanisms.",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",Healthcare assistant prompt,"根据提供的医疗信息，饮酒超过推荐量对心脏病风险有以下影响：

1. **升高血压** - 过量饮酒会提高血压水平

2. **增加体重** - 酒精含有额外的卡路里，可能导致体重增加

3. **增加心脏病风险** - 高血压和体重增加这两个因素都会提高患心脏病的风险

**推荐的饮酒量：**
- 男性：每天不超过2杯
- 女性：每天不超过1杯

医疗建议指出，最好不要饮酒。如果您确实饮酒，应严格控制在推荐量以内，以降低心脏病风险。","根据提供的医疗信息，饮酒超过建议量会对心脏病风险产生以下影响：

1. **升高血压** - 过量饮酒会升血压

2. **增加额外热量导致体重增加** - 血压升高和体重增加都会增加患心脏病的风险

为尽量减少这些风险而建议的限制是：
- **男士**：每天饮酒不超过 2 杯
- **女性**：每天饮酒不超过 1 杯

上下文强调最好根本不喝酒，但如果您选择喝酒，保持在这些限制范围内对心脏健康很重要。饮酒量超过推荐量会通过多种机制直接增加患心脏病的风险。",7.1269426345825195,7.378464221954346,0.025359392166137695,0.7135608196258545,7.101583242416382,6.664903402328491,claude-sonnet-4-5-20250929,True
男性和女性减少心脏病风险的饮酒指南是什么？,chinese,What are the drinking guidelines for men and women to reduce the risk of heart disease?,". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)","Based on the medical information provided, guidelines for drinking to reduce the risk of heart disease are as follows:

**Men:** No more than 2 alcoholic drinks per day

**Female:** No more than 1 alcoholic drink per day

**BEST ADVICE:** It’s best not to drink alcohol

**Cause:** Drinking alcohol increases blood pressure and adds extra calories, which may lead to weight gain. Both increase the risk of heart disease.

If you are considering changing your drinking habits to reduce your risk of heart disease, it is recommended to talk to your healthcare provider for personalized advice.","Based on the provided context, the drinking guidelines to reduce the risk of heart disease are:

**For men:** No more than 2 drinks per day

**For women:** No more than 1 drink per day

The context notes that while it's best not to drink alcohol at all, these are the recommended limits if you do choose to drink. Alcohol can raise blood pressure and add extra calories that may cause weight gain, both of which increase the risk of heart disease.",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for reva
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten",Healthcare assistant prompt,"根据提供的医疗信息，减少心脏病风险的饮酒指南如下：

**男性：** 每天不超过2杯酒精饮料

**女性：** 每天不超过1杯酒精饮料

**最佳建议：** 最好不要饮酒

**原因：** 饮酒会升高血压并增加额外热量，可能导致体重增加。这两者都会增加心脏病风险。

如果您正在考虑改变饮酒习惯以降低心脏病风险，建议咨询您的医疗保健提供者以获得个性化的建议。","根据所提供的情况，降低心脏病风险的饮酒指南是：

**对于男性：** 每天饮酒不超过 2 杯

**对于女性：** 每天饮酒不超过 1 杯

上下文指出，虽然最好根本不喝酒，但如果您选择喝酒，这些是建议的限制。酒精会升高血压并增加额外的热量，从而可能导致体重增加，这两者都会增加患心脏病的风险。",6.591068744659424,6.2602715492248535,0.032163143157958984,0.5850989818572998,6.558905601501465,5.675172567367554,claude-sonnet-4-5-20250929,True
管理压力如何影响心脏病风险？,chinese,How does managing stress affect heart disease risk?,". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage your stress include exercise, listening to music, focusing on something calm or peaceful, and meditating.Managing diabetes.Having diabetes doubles your risk ofdiabetic heart disease. That is because over time,high blood glucose(blood sugar) from diabetes can damage your blood vessels and the nerves that control your heart and blood vessels. So, it is important to gettested for diabetes, and if you have it, to keep it under control.Getting enough sleep.If you don't get enough sleep, you raise your risk of high blood pressure, obesity, and diabetes. Those three things can raise your risk of heart disease

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure, which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy, is a contraindication to beta blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn (see DOSAGE AND ADMINISTRATION )

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn

WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In patients with acute myocardial infarction, cardiac failure which is not promptly and effectively controlled by 80 mg of intravenous furosemide or equivalent therapy is a contraindication to beta-blocker treatment. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. If cardiac failure continues despite adequate treatment, atenolol should be withdrawn","According to the medical information provided, managing stress has an important impact on heart disease risk:

## Effects of stress on the heart:

1. **Extreme stress may be a ""trigger"" for heart attack**

2. **Poor ways of coping with stress can increase the risk of heart disease**, including:
   - Overeating
   - Alcoholism
   - Smoking

## Effective stress management methods:

The following methods can help manage stress and thereby reduce the risk of heart disease:

- **Exercise Exercise**
- **Listen to music**
- **Focus on something calm or tranquil**
- **Meditation**

## Related risk factors:

Improper stress management can also lead to:
- Lack of sleep
- high blood pressure
- Obesity
- Diabetes

These factors further increase the risk of heart disease.

**Summary**: Good stress management is crucial to reducing the risk of heart disease. Adopting healthy ways to deal with stress and avoiding bad habits can effectively protect your heart health.","Based on the provided context, managing stress can help reduce heart disease risk in several important ways:

**Direct Impact:**
Extreme stress can act as a ""trigger"" for a heart attack, making stress management an important preventive measure.

**Indirect Impact:**
Many common but unhealthy coping mechanisms for stress are harmful to heart health, including:
- Overeating
- Heavy drinking
- Smoking

**Recommended Stress Management Techniques:**
The context suggests several healthy ways to manage stress that can benefit heart health:
- Exercise
- Listening to music
- Focusing on something calm or peaceful
- Meditating

By managing stress through these healthier methods rather than unhealthy coping mechanisms, you can reduce your risk of heart disease. Additionally, proper stress management may help prevent stress from acting as a trigger for acute cardiac events like heart attacks.

It's worth noting that stress management is part of a comprehensive approach to heart health that should also include managing other risk factors like diabetes, blood pressure, getting adequate sleep, and maintaining a healthy lifestyle.",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres",". Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart. Some ways to help manage 
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres
---
WARNINGS: WARNINGS Cardiac Failure Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depres",Healthcare assistant prompt,"根据提供的医学信息，管理压力对心脏病风险有重要影响：

## 压力对心脏的影响：

1. **极度压力可能是心脏病发作的""触发因素""**

2. **不良的压力应对方式会增加心脏病风险**，包括：
   - 暴饮暴食
   - 酗酒
   - 吸烟

## 有效的压力管理方法：

以下方法可以帮助管理压力，从而降低心脏病风险：

- **运动锻炼**
- **听音乐**
- **专注于平静或宁静的事物**
- **冥想**

## 相关风险因素：

压力管理不当还可能导致：
- 睡眠不足
- 高血压
- 肥胖
- 糖尿病

这些因素都会进一步增加心脏病风险。

**总结**：良好的压力管理对于降低心脏病风险至关重要。采用健康的方式应对压力，避免不良习惯，可以有效保护心脏健康。","根据所提供的背景，管理压力可以通过几个重要的方式帮助降低心脏病风险：

**直接影响：**
极度压力可能会成为心脏病发作的“触发因素”，因此压力管理成为一项重要的预防措施。

**间接影响：**
许多常见但不健康的压力应对机制有害心脏健康，包括：
- 暴饮暴食
- 大量饮酒
- 吸烟

**推荐的压力管理技巧：**
本文提出了几种有益于心脏健康的压力管理方法：
- 锻炼
- 听音乐
- 专注于平静或平和的事情
- 冥想

通过这些更健康的方法而不是不健康的应对机制来管理压力，您可以降低患心脏病的风险。此外，适当的压力管理可能有助于防止压力引发心脏病等急性心脏事件。

值得注意的是，压力管理是心脏健康综合方法的一部分，还应包括管理其他风险因素，如糖尿病、血压、充足的睡眠和保持健康的生活方式。",8.494370222091675,8.371788501739502,0.044513702392578125,0.440629243850708,8.449856519699097,7.931159257888794,claude-sonnet-4-5-20250929,True
吸烟者降低心脏病风险的建议措施是什么？,chinese,What are the recommended steps for smokers to reduce their risk of heart disease?,". Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain heart diseases by makingheart-healthy lifestyle changesand managing any other medical conditions you have.NIH: National Heart, Lung, and Blood Institute",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain heart diseases by makingheart-healthy lifestyle changesand managing any other medical conditions you have.NIH: National Heart, Lung, and Blood Institute

. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have. Possible treatments may include: You may be able to lower your risk of certain heart diseases by makingheart-healthy lifestyle changesand managing any other medical conditions you have. NIH: National Heart, Lung, and Blood Institute","Based on the medical information provided, recommended actions for smokers to reduce the risk of heart disease are:

**Quit smoking**

Specific instructions:
- Smoking raises blood pressure and increases the risk of heart attack and stroke
- If you don't smoke, don't start smoking
- If you smoke, **quitting smoking can reduce your risk of heart disease**
- You can talk to your healthcare provider to help find the best way to quit smoking for you

Additionally, comprehensive cardiovascular risk management includes:
- Control blood pressure
- Blood lipid management
- Diabetes management
- Antithrombotic therapy
- Exercise
- Limit sodium intake
- Manage stress
- Limit alcohol consumption

Quitting smoking is one of the most important steps you can take to reduce your risk of heart disease.","Based on the provided medical information, the recommended steps for smokers to reduce their risk of heart disease include:

1. **Smoking cessation** - This is explicitly mentioned as part of comprehensive cardiovascular risk management.

2. **Comprehensive cardiovascular risk management**, which includes:
   - Blood pressure control (if hypertension is present)
   - Lipid control (cholesterol management)
   - Diabetes management (if applicable)
   - Antithrombotic therapy (when appropriate)
   - Regular exercise
   - Limited sodium intake

3. **Heart-healthy lifestyle changes** - The context emphasizes that making these changes can help lower the risk of heart disease.

4. **Managing other medical conditions** - Any existing health conditions should be properly controlled.

The medical information clearly identifies smoking as a significant risk factor for coronary heart disease. In patients with multiple risk factors including smoking, medications like atorvastatin (for cholesterol) and antihypertensive drugs (for blood pressure) may be indicated to reduce the risk of myocardial infarction, stroke, and other cardiovascular events.

The most critical step for smokers specifically is **smoking cessation**, combined with the other cardiovascular risk management strategies mentioned above.",". Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain hear",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Possible treatments may include:Heart-healthy lifestyle changesMedicinesProcedures orsurgeriesCardiac rehabilitationCan heart diseases be prevented?You may be able to lower your risk of certain hear
---
. Treatment plans for heart disease depend on the type of heart disease you have, how serious your symptoms are, and what other health conditions you have. Possible treatments may include: You may be ",Healthcare assistant prompt,"根据提供的医疗信息，对于吸烟者降低心脏病风险的建议措施是：

**戒烟**

具体说明：
- 吸烟会升高血压，并增加心脏病发作和中风的风险
- 如果您不吸烟，就不要开始吸烟
- 如果您吸烟，**戒烟可以降低您患心脏病的风险**
- 您可以咨询医疗保健提供者，帮助找到最适合您的戒烟方法

此外，综合心血管风险管理还包括：
- 控制血压
- 血脂管理
- 糖尿病管理
- 抗血栓治疗
- 运动锻炼
- 限制钠摄入
- 管理压力
- 限制饮酒

戒烟是降低心脏病风险最重要的措施之一。","根据所提供的医疗信息，建议吸烟者降低患心脏病风险的步骤包括：

1. **戒烟** - 作为全面心血管风险管理的一部分，明确提到了这一点。

2. **全面的心血管风险管理**，其中包括：
   - 血压控制（如果存在高血压）
   - 脂质控制（胆固醇管理）
   - 糖尿病管理（如果适用）
   - 抗血栓治疗（适当时）
   - 定期锻炼
   - 限制钠摄入量

3. **改变有益于心脏健康的生活方式** - 上下文强调做出这些改变有助于降低患心脏病的风险。

4. **管理其他医疗状况** - 任何现有的健康状况都应得到适当控制。

医学信息清楚地表明吸烟是冠心病的重要危险因素。对于具有吸烟等多种危险因素的患者，阿托伐他汀（针对胆固醇）和抗高血压药物（针对血压）等药物可能有助于降低心肌梗塞、中风和其他心血管事件的风险。

对于吸烟者来说，最关键的一步是**戒烟**，并结合上述其他心血管风险管理策略。",6.923223257064819,8.385154962539673,0.030929088592529297,0.4502720832824707,6.89229416847229,7.934882879257202,claude-sonnet-4-5-20250929,True
戒烟对心脏病风险有什么影响？,chinese,What impact does quitting smoking have on heart disease risk?,". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .

. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship between medication use and events, a contributory role of varenicline cannot be ruled out [see Warnings and Precautions (5.5) ] . There have been reports of hyperglycemia in patients following initiation of varenicline. There have been reports of somnambulism, some resulting in harmful behavior to self, others, or property in patients treated with varenicline [see Warnings and Precautions (5.6) ] .",". Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. Venous Events Use of COCs increases the risk of venous thromboembolic events (VTEs), such as deep vein thrombosis and pulmonary embolism. Risk factors for VTEs include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs [see Contraindications (4) ] . While the increased risk of VTE associated with use of COCs is well-established, the rates of VTE are even greater during pregnancy, and especially during the postpartum period (see Figure 1). The rate of VTE in females using COCs has been estimated to be 3 to 9 cases per 10,000 woman years

. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking","According to the medical information provided, quitting smoking has the following important effects on heart disease risk:

## Benefits of quitting smoking:

**REDUCED RISK OF HEART DISEASE**: If you smoke, quitting smoking will reduce your risk of heart disease.

## Dangers of smoking:

1. **Raise blood pressure**: Smoking can increase blood pressure

2. **Increased risk of cardiovascular events**:
   - Increased risk of heart attack
   - Increased risk of stroke

3. **Stress Related**: Smoking is a bad way to cope with stress, and stress itself is linked to heart disease

## Suggestions:

- **If you don't smoke**: Don't start smoking
- **If you smoke**: You should quit smoking
- **Get help**: You can talk to your healthcare provider to find the best way to quit smoking for you

In short, quitting smoking is one of the important measures to reduce the risk of heart disease and has a significant protective effect on cardiovascular health.","Based on the provided medical information, **quitting smoking lowers your risk of heart disease**.

The context specifically states that ""If you do smoke, quitting will lower your risk of heart disease."" 

The information also explains why smoking is harmful to cardiovascular health:
- Cigarette smoking raises your blood pressure
- It puts you at higher risk of heart attack and stroke
- It increases the risk of serious cardiovascular events

Additionally, the context notes that stress-related coping mechanisms like smoking are bad for your heart, and that not smoking is an important preventive measure for heart disease.

The medical sources also mention that nicotine replacement products can help reduce withdrawal symptoms, including nicotine craving, which can assist people in their efforts to quit smoking.",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be
---
. In the majority of the reported cases, patients had pre-existing cardiovascular disease and/or other risk factors. Although smoking is a risk factor for MI and CVA, based on temporal relationship be",". Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. Iclevia is contraindicated in women over 35 years of age who smoke [ see Contraindications (4) ]. Cigarette smoking increases the risk of serious cardiovascular events from COC use. This risk increa
---
. It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking
---
INDICATIONS AND USAGE: Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking",Healthcare assistant prompt,"根据提供的医学信息，戒烟对心脏病风险有以下重要影响：

## 戒烟的益处：

**降低心脏病风险**：如果您吸烟，戒烟将降低您患心脏病的风险。

## 吸烟的危害：

1. **升高血压**：吸烟会使血压升高

2. **增加心血管事件风险**：
   - 增加心脏病发作的风险
   - 增加中风的风险

3. **压力相关**：吸烟是应对压力的不良方式之一，而压力本身也与心脏病有关

## 建议：

- **如果您不吸烟**：不要开始吸烟
- **如果您吸烟**：应该戒烟
- **寻求帮助**：您可以与医疗保健提供者讨论，找到最适合您的戒烟方法

总之，戒烟是降低心脏病风险的重要措施之一，对心血管健康有显著的保护作用。","根据提供的医疗信息，**戒烟可以降低患心脏病的风险**。

上下文特别指出“如果您吸烟，戒烟会降低患心脏病的风险”。 

该信息还解释了为什么吸烟有害心血管健康：
- 吸烟会导致血压升高
- 它会使您患心脏病和中风的风险更高
- 它会增加严重心血管事件的风险

此外，上下文还指出，与压力相关的应对机制（例如吸烟）对心脏有害，而不吸烟是心脏病的重要预防措施。

医学消息人士还提到，尼古丁替代产品可以帮助减少戒断症状，​​包括对尼古丁的渴望，这可以帮助人们戒烟。",7.870481967926025,7.4552154541015625,0.03441500663757324,0.4869053363800049,7.836066961288452,6.968310117721558,claude-sonnet-4-5-20250929,True
女性饮酒以降低心脏病风险的指南是什么？,chinese,What are the guidelines for women drinking alcohol to reduce their risk of heart disease?,". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Have no more than 1 drink per day if you are a woman.Not smoking.Cigarette smokingraises your blood pressure and puts you at higher risk of heart attack andstroke.If you do not smoke, don't start.If you do smoke,quittingwill lower your risk of heart disease. You can talk with your health care provider for help in finding the best way for you to quit.Managing stress.Stressis linked to heart disease in many ways. It can raise your blood pressure. Extreme stress can be a ""trigger"" for a heart attack. Also, some common ways of coping with stress, such as overeating, heavy drinking, and smoking, are bad for your heart

. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)

evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property

. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 5.3 ) Accidental Injury: Accidental injuries (e.g., traffic accidents) have been reported. Instruct patients to use caution driving or operating machinery until they know how varenicline may affect them. ( 5.4 ) Cardiovascular Events: Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke. ( 5.5 and 6.1 ) Somnambulism: Cases of somnambulism have been reported in patients taking varenicline. Some cases described harmful behavior to self, others, or property","According to the medical information provided, **drinking alcohol does not reduce the risk of heart disease**. On the contrary, drinking alcohol increases the risk of heart disease.

Specific guidelines are as follows:

**For Women:**
- If drinking, no more than 1 drink per day

**IMPORTANT NOTE:**
- Alcohol can raise blood pressure
- Alcohol adds extra calories and may lead to weight gain
- Both increase the risk of heart disease
- **Better not drink alcohol**

Therefore, drinking restrictions are for **harm reduction**, not for reducing heart disease risk. Ways to truly reduce your risk of heart disease include:
- no smoking
- Control blood pressure
- Manage stress
- healthy eating
- Moderate exercise
- Limit sodium intake","Based on the provided medical context, there is no specific information about guidelines for women drinking alcohol to reduce their risk of heart disease.

The context primarily discusses:
1. Atorvastatin calcium tablets for cardiovascular disease prevention in various patient populations
2. Varenicline (a smoking cessation medication) and its interaction with alcohol, which mentions that patients should ""reduce the amount of alcohol they consume"" while taking this medication

However, these references do not provide guidelines about alcohol consumption for heart disease prevention in women specifically. To get accurate information about alcohol consumption guidelines for cardiovascular health in women, you would need to consult other medical sources or speak with a healthcare provider.",". It also adds extra calories, which may cause weight gain. Both of those raise your risk of heart disease. It's best not to drink, but if you do:Have no more than 2 drinks per day if you are a man.Ha
---
. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihyperten
---
evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for reva",". 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hyperten
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( 
---
. ( 5.2 ) Interaction with Alcohol: Increased effects of alcohol have been reported. Instruct patients to reduce the amount of alcohol they consume until they know whether varenicline affects them. ( ",Healthcare assistant prompt,"根据提供的医疗信息，**饮酒并不能降低心脏病风险**。相反，饮酒会增加心脏病风险。

具体指南如下：

**对于女性：**
- 如果饮酒，每天不超过1杯

**重要提示：**
- 酒精会升高血压
- 酒精会增加额外热量，可能导致体重增加
- 这两者都会增加心脏病风险
- **最好不要饮酒**

因此，饮酒限制是为了**减少伤害**，而不是为了降低心脏病风险。真正降低心脏病风险的方法包括：
- 不吸烟
- 控制血压
- 管理压力
- 健康饮食
- 适量运动
- 限制钠摄入","根据所提供的医学背景，没有关于女性饮酒以降低患心脏病风险的指南的具体信息。

上下文主要讨论：
1.阿托伐他汀钙片用于各类患者人群心血管疾病的预防
2. Varenicline（一种戒烟药物）及其与酒精的相互作用，其中提到患者在服用该药物时应“减少饮酒量”

然而，这些参考文献并未专门提供有关饮酒预防女性心脏病的指南。要获得有关女性心血管健康的饮酒指南的准确信息，您需要咨询其他医疗来源或与医疗保健提供者交谈。",7.108144760131836,7.300868511199951,0.02733778953552246,0.4768955707550049,7.0808069705963135,6.823972940444946,claude-sonnet-4-5-20250929,True
盐酸甲哌卡因用于什么？,chinese,What is mepivacaine hydrochloride used for?,"CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride

DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 6.5 (5.0 to 7.0). Lidocaine has cardiac antiarrhythmic properties and is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-2′,6′-acetoxylidide monohydrochloride monohydrate, a white powder freely soluble in water. It has the following structural formula: structural formula lidocaine hydrochloride","According to the English medical information provided, it does not contain relevant information about Mepivacaine Hydrochloride.

The content provided relates only to clinical pharmacology information of glucocorticoids (such as hydrocortisone and cortisone), including their anti-inflammatory effects, alternative therapeutic uses, and effects on the metabolic and immune systems.

If you want to know the usage information of mepivacaine hydrochloride, you need to consult other relevant medical information.","Based on the provided context, mepivacaine hydrochloride is a local anesthetic used for:

1. **Local infiltration** - injecting the anesthetic directly into tissue
2. **Peripheral nerve block** - blocking specific nerves to numb a region
3. **Caudal epidural blocks** - anesthesia in the lower spine/sacral region
4. **Lumbar epidural blocks** - anesthesia in the lower back region

It is available as sterile isotonic solutions in concentrations of 1%, 1.5%, and 2% for injection. Mepivacaine hydrochloride belongs to the amide-type class of local anesthetics and works by blocking nerve conduction to provide regional anesthesia for medical procedures.","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor","DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so
---
DESCRIPTION: 1.1 DESCRIPTION 4% Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution containing lidocaine hydrochloride, anhydrous 40 mg/mL in water for injection. May contain so",Healthcare assistant prompt,"根据提供的英文医学信息内容,其中并未包含关于盐酸甲哌卡因(Mepivacaine Hydrochloride)的相关信息。

所提供的内容仅涉及糖皮质激素(如氢化可的松和可的松)的临床药理学信息,包括它们的抗炎作用、替代治疗用途以及对代谢和免疫系统的影响。

如需了解盐酸甲哌卡因的用途信息,需要查阅其他相关的医学资料。","根据所提供的情况，盐酸甲哌卡因是一种局部麻醉剂，用于：

1. **局部浸润** - 将麻醉剂直接注射到组织中
2. **周围神经阻滞** - 阻滞特定神经以麻木某个区域
3. **尾部硬膜外阻滞** - 下部脊柱/骶骨区域的麻醉
4. **腰椎硬膜外阻滞** - 下背部区域麻醉

它可作为注射用浓度为 1%、1.5% 和 2% 的无菌等渗溶液。盐酸甲哌卡因属于酰胺类局部麻醉药，通过阻断神经传导为医疗操作提供区域麻醉。",10.268770694732666,7.174109220504761,0.03265881538391113,0.5321190357208252,10.236111879348755,6.6419901847839355,claude-sonnet-4-5-20250929,True
哌替啶盐酸盐的结构式是什么？,chinese,What is the structural formula of pethidine hydrochloride?,"DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure: Divalproex sodium, USP occurs as a white crystalline powder with a characteristic odor. Divalproex sodium extended-release 250 and 500 mg tablets are for oral administration. Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid

DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure: Divalproex sodium, USP occurs as a white crystalline powder with a characteristic odor. Divalproex sodium extended-release 250 and 500 mg tablets are for oral administration. Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid

DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure: Divalproex sodium, USP occurs as a white crystalline powder with a characteristic odor. Divalproex sodium extended-release 250 and 500 mg tablets are for oral administration. Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid

. Sulfuric acid and, if necessary, sodium hydroxide may be added to adjust pH (4.0 – 5.5). Preservative: benzalkonium chloride 0.004% Trimethoprim sulfate (Structural formula) Polymyxin B Sulfate, the sulfate salt of polymyxin B1 and B2 (Structural formula)

DESCRIPTION: DESCRIPTION Levothyroxine Sodium Tablets, USP contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T 4 ) sodium]. Synthetic T 4 is identical to that produced in the human thyroid gland. Levothyroxine (T 4 ) sodium has an empirical formula of C 15 H 10 I 4 N NaO 4 • H 2 O, molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown: Chemical Structure Inactive Ingredients Colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, corn starch, acacia and sodium starch glycolate. The following are the coloring additives per tablet strength: Strength (mcg) Color Additive(s) 25 FD&C Yellow No. 6 Aluminum Lake 50 None 75 FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake 88 D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake 100 D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake 112 D&C Red No. 27 Aluminum Lake 125 FD&C Yellow No",". Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, pregelatinized starch (corn), sodium lauryl sulfate, titanium dioxide and triacetin. The 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg and 320 mg/12.5 mg tablets also contain red iron oxide and yellow iron oxide. The 320 mg/25 mg tablet also contains FD&C Blue No. 2 Aluminum Lake and FD&C Yellow No

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, pregelatinized starch (corn), sodium lauryl sulfate, titanium dioxide and triacetin. The 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg and 320 mg/12.5 mg tablets also contain red iron oxide and yellow iron oxide. The 320 mg/25 mg tablet also contains FD&C Blue No. 2 Aluminum Lake and FD&C Yellow No","Based on the medical information provided, I was unable to find any information on the structural formula of Meperidine Hydrochloride.

The document content provided mainly includes descriptions of the following drugs:
- Divalproex sodium
-Polymyxin B Sulfate
- Levothyroxine Sodium

However, there is no chemical structure or related information related to pethidine hydrochloride.

If you want to know the structural formula of pethidine hydrochloride, it is recommended to consult the specific instructions or pharmacopoeia information of the drug.","Based on the provided context, I cannot answer your question about the structural formula of pethidine hydrochloride. The context only contains information about hydrochlorothiazide and valsartan combination tablets. There is no information about pethidine hydrochloride in the provided medical sources.

To obtain accurate information about pethidine hydrochloride's structural formula, you would need to consult different FDA or NIH sources that specifically cover that medication.","DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralizatio
---
DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralizatio
---
DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralizatio
---
. Sulfuric acid and, if necessary, sodium hydroxide may be added to adjust pH (4.0 – 5.5). Preservative: benzalkonium chloride 0.004% Trimethoprim sulfate (Structural formula) Polymyxin B Sulfate, the
---
DESCRIPTION: DESCRIPTION Levothyroxine Sodium Tablets, USP contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T 4 ) sodium]. Synthetic T 4 is identical to that pr",". Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H ",Healthcare assistant prompt,"根据提供的医疗信息内容，我无法找到关于哌替啶盐酸盐（Meperidine Hydrochloride）结构式的相关信息。

提供的文档内容主要包含以下药物的描述：
- 双丙戊酸钠（Divalproex sodium）
- 多粘菌素B硫酸盐（Polymyxin B Sulfate）
- 左甲状腺素钠（Levothyroxine Sodium）

但没有涉及哌替啶盐酸盐的化学结构或相关信息。

如需了解哌替啶盐酸盐的结构式，建议查阅该药物的专门说明书或药典资料。","根据所提供的情况，我无法回答你关于盐酸哌替啶结构式的问题。上下文仅包含有关氢氯噻嗪和缬沙坦组合片的信息。所提供的医疗来源中没有有关盐酸哌替啶的信息。

要获得有关盐酸哌替啶结构式的准确信息，您需要咨询专门涵盖该药物的不同 FDA 或 NIH 来源。",7.24275279045105,5.549336910247803,0.027405977249145508,0.4636051654815674,7.215346813201904,5.085731744766235,claude-sonnet-4-5-20250929,True
血浆蛋白在局部麻醉药作用中的角色是什么？,chinese,What is the role of plasma proteins in the action of local anesthetics?,"CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Cholesterol and triglycerides circulate in the bloodstream as part of lipoprotein complexes. With ultracentrifugation, these complexes separate into HDL (high-density lipoprotein), IDL (intermediate-density lipoprotein), LDL (low-density lipoprotein), and VLDL (very-low-density lipoprotein) fractions. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. LDL is formed from VLDL and is catabolized primarily through the high-affinity LDL receptor

. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see Drug Interactions (7.1) ]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. Excretion Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration

. The metabolites are observed in the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. In vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by others and may result in little change in overall rates of ondansetron elimination. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron

. The metabolites are observed in the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. In vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by others and may result in little change in overall rates of ondansetron elimination. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron

. The metabolites are observed in the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. In vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolizing ondansetron, it is likely that inhibition or loss of one enzyme (e.g., CYP2D6 genetic deficiency) will be compensated by others and may result in little change in overall rates of ondansetron elimination. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron",". It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been identified from human adults: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2′,6′-pipecoloxylidide). Mepivacaine does not ordinarily produce irritation or tissue damage, and does not cause methemoglobinemia when administered in recommended doses and concentrations.

. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacaine is approximately 75% bound to plasma proteins. The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation. Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain. Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or renal disease, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient

. The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The duration of anesthesia also varies depending upon the technique and type of block, the concentration, and the individual. Mepivacaine will normally provide anesthesia which is adequate for 2 to 2 1 / 2 hours of surgery. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma. Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by the degree of plasma protein binding, the degree of ionization, and the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer

. In vitro , etoposide is highly protein bound (97%) to human plasma proteins. An inverse relationship between plasma albumin levels and etoposide renal clearance is found in children. In a study determining the effect of other therapeutic agents on the in vitro binding of carbon-14 labeled etoposide to human serum proteins, only phenylbutazone, sodium salicylate, and aspirin displaced protein-bound etoposide at concentrations achieved in vivo . Etoposide binding ratio correlates directly with serum albumin in patients with cancer and in normal volunteers. The unbound fraction of etoposide significantly correlated with bilirubin in a population of cancer patients. Data have suggested a significant Inverse correlation between serum albumin concentration and free fraction of etoposide

. Distribution In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion metabolite is similar to that for bupropion, whereas the extent of protein binding of the threohydrobupropion metabolite is about half that seen with bupropion. Metabolism Bupropion is extensively metabolized in humans. Three metabolites are active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group. In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion","Based on the medical literature provided, I am unable to answer the question regarding the role of plasma proteins in the action of local anesthetics.

The literature provided mainly involves:
1. **Atorvastatin** - Pharmacological mechanism and metabolism of a lipid-lowering drug
2. **Ondansetron** - Metabolism pathway of an antiemetic drug

These contents have nothing to do with the role of local anesthetics and plasma proteins in local anesthesia.

To answer your question, it is necessary to provide pharmacological information about local anesthetics (such as lidocaine, bupivacaine, etc.), especially regarding the binding of drugs to plasma proteins.","Based on the provided context, plasma proteins play several important roles in the action of local anesthetics:

1. **Binding and Distribution**: Local anesthetics are bound to plasma proteins in varying degrees. For example, mepivacaine is approximately 75% bound to plasma proteins. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.

2. **Placental Transfer**: Plasma protein binding is crucial in determining placental transfer of local anesthetics. There is an **inverse relationship** between the degree of plasma protein binding and fetal/maternal ratios - only the **free, unbound drug** is available for placental transfer. This means drugs that are more highly bound to plasma proteins will have less transfer across the placenta to the fetus.

3. **Drug Availability**: The protein-bound portion of the drug serves as a reservoir, while only the free, unbound fraction is pharmacologically active and available for:
   - Placental transfer
   - Distribution to tissues
   - Metabolism and elimination

4. **Clinical Significance**: The extent of protein binding, along with factors like degree of ionization and lipid solubility, governs the rate and degree of drug diffusion throughout the body, including across the placenta by passive diffusion.

In summary, plasma protein binding acts as a regulatory mechanism that controls the amount of free drug available for pharmacological action and distribution, particularly important in pregnant patients where placental transfer is a concern.","CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-met
---
. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 
---
. The metabolites are observed in the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. In vitro metabolism studies ha
---
. The metabolites are observed in the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. In vitro metabolism studies ha
---
. The metabolites are observed in the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. In vitro metabolism studies ha",". It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been ide
---
. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacain
---
. The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The du
---
. In vitro , etoposide is highly protein bound (97%) to human plasma proteins. An inverse relationship between plasma albumin levels and etoposide renal clearance is found in children. In a study dete
---
. Distribution In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL. The extent of protein binding of the hydroxybupropion metabolite is similar ",Healthcare assistant prompt,"根据提供的医学文献内容,我无法回答关于血浆蛋白在局部麻醉药作用中的角色这个问题。

提供的文献内容主要涉及:
1. **阿托伐他汀(Atorvastatin)** - 一种降脂药物的药理机制和代谢
2. **昂丹司琼(Ondansetron)** - 一种止吐药物的代谢途径

这些内容都与局部麻醉药及血浆蛋白在局部麻醉中的作用无关。

要回答您的问题,需要提供关于局部麻醉药(如利多卡因、布比卡因等)的药理学信息,特别是关于药物与血浆蛋白结合的相关内容。","根据所提供的背景，血浆蛋白在局部麻醉药的作用中发挥着几个重要作用：

1. **结合和分布**：局麻药不同程度地与血浆蛋白结合。例如，甲哌卡因大约 75% 与血浆蛋白结合。一般来说，药物的血浆浓度越低，药物与血浆结合的百分比越高。

2. **胎盘转移**：血浆蛋白结合对于决定局部麻醉药的胎盘转移至关重要。血浆蛋白结合程度与胎儿/母体比率之间存在**反比关系** - 只有**游离、未结合的药物**可用于胎盘移植。这意味着与血浆蛋白结合程度较高的药物通过胎盘转移到胎儿的能力会较少。

3. **药物可用性**：药物的蛋白质结合部分充当储库，而只有游离的未结合部分具有药理活性并可用于：
   - 胎盘移植
   - 分布到组织
   - 新陈代谢和消除

4. **临床意义**：蛋白质结合的程度以及电离度和脂溶性等因素决定了药物在全身扩散的速率和程度，包括通过被动扩散穿过胎盘。

总之，血浆蛋白结合作为一种调节机制，控制可用于药理作用和分布的游离药物的量，这对于考虑胎盘转移的妊娠患者尤其重要。",8.434354066848755,9.945372581481934,0.04035019874572754,0.438812255859375,8.394003868103027,9.506560325622559,claude-sonnet-4-5-20250929,True
什么浓度的盐酸甲哌卡因可以提供完全的感觉和运动阻滞？,chinese,What concentration of mepivacaine hydrochloride provides complete sensory and motor blockade?,". These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid-like symptomatology (including severe hypotension). Cross sensitivity among members of the amide-type local anesthetic group has been reported. The usefulness of screening for sensitivity has not been definitely established. Neurologic The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient. Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug

. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt intake should be carefully monitored in order to avoid the development of hypertension, edema or weight gain. Periodic checking of serum electrolyte levels is advisable during prolonged therapy; dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Patients should not be vaccinated against smallpox while on corticosteroid therapy. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response

. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt intake should be carefully monitored in order to avoid the development of hypertension, edema or weight gain. Periodic checking of serum electrolyte levels is advisable during prolonged therapy; dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Patients should not be vaccinated against smallpox while on corticosteroid therapy. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response

. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt intake should be carefully monitored in order to avoid the development of hypertension, edema or weight gain. Periodic checking of serum electrolyte levels is advisable during prolonged therapy; dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Patients should not be vaccinated against smallpox while on corticosteroid therapy. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response

. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt intake should be carefully monitored in order to avoid the development of hypertension, edema or weight gain. Periodic checking of serum electrolyte levels is advisable during prolonged therapy; dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Patients should not be vaccinated against smallpox while on corticosteroid therapy. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The duration of anesthesia also varies depending upon the technique and type of block, the concentration, and the individual. Mepivacaine will normally provide anesthesia which is adequate for 2 to 2 1 / 2 hours of surgery. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma. Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by the degree of plasma protein binding, the degree of ionization, and the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer

. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition of Available Solutions In Water For Injection 1% Single Dose 30 mL Vial mg/mL 1% Multiple Dose 50 mL Vial mg/mL 1.5% Single Dose 30 mL Vial mg/mL 2% Single Dose 20 mL Vial mg/mL 2% Multiple Dose 50 mL Vial mg/mL Mepivacaine hydrochloride 10 10 15 20 20 Sodium chloride 6.6 7 5.6 4.6 5 Potassium chloride 0.3 0.3 0.3 Calcium chloride 0.33 0.33 0.33 Methylparaben 1 1 The pH of the solution is adjusted between 4.5 and 6.8 with sodium hydroxide or hydrochloric acid. chemical structure

DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 15 H 22 N 2 O HCl. It is a white, crystalline odorless powder, soluble in water, but very resistant to both acid and alkaline hydrolysis. Mepivacaine hydrochloride is a local anesthetic available as sterile isotonic solutions (clear, colorless) in concentrations of 1%, 1.5% and 2% for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group

. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been identified from human adults: two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2′,6′-pipecoloxylidide). Mepivacaine does not ordinarily produce irritation or tissue damage, and does not cause methemoglobinemia when administered in recommended doses and concentrations.

DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0. Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows: C 15 H 21 NO 2 •HCl MW 283.79 image of chemical structure","Based on the medical information provided in English, I was unable to find specific information on the relationship between mepivacaine hydrochloride concentrations and sensory and motor blockade.

The text provided primarily discusses:
1. Allergic reactions and neurological adverse reactions to local anesthetics
2. Side effects and precautions of corticosteroid drugs such as fludrocortisone acetate

None of this information relates to the concentration and blocking effects of mepivacaine hydrochloride.

For information on specific concentrations of mepivacaine hydrochloride, it is recommended to consult the full package insert for the drug or consult a medical professional.","Based on the provided context, **2% concentration of mepivacaine hydrochloride** will produce complete sensory and motor block of any nerve group.

The context also notes that the 1.5% solution will provide extensive and often complete motor block, but the 2% concentration is specifically stated to produce complete sensory AND motor block.",". These reactions are characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excess
---
. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt 
---
. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt 
---
. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt 
---
. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt ",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The du
---
. Mepivacaine hydrochloride is related chemically and pharmacologically to the amide-type local anesthetics. It contains an amide linkage between the aromatic nucleus and the amino group. Composition 
---
DESCRIPTION: DESCRIPTION Mepivacaine hydrochloride is 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride and has the following structural formula: The molecular formula is C 
---
. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been ide
---
DESCRIPTION: DESCRIPTION Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic. Each mL of the DOSETTE vial cont",Healthcare assistant prompt,"根据提供的英文医疗信息内容，我无法找到关于盐酸甲哌卡因(mepivacaine hydrochloride)浓度与感觉和运动阻滞关系的具体信息。

提供的文本主要讨论了：
1. 局部麻醉药的过敏反应和神经系统不良反应
2. 氟氢可的松(fludrocortisone acetate)这种皮质类固醇药物的副作用和注意事项

这些内容都不涉及盐酸甲哌卡因的浓度和阻滞效果的相关信息。

如需了解盐酸甲哌卡因的具体浓度使用信息，建议查阅该药物的完整说明书或咨询医疗专业人员。","根据所提供的情况，**2% 浓度的盐酸甲哌卡因**将对任何神经群产生完全的感觉和运动阻滞。

上下文还指出，1.5% 的溶液将提供广泛且通常完整的运动阻滞，但 2% 的浓度专门说明可产生完全的感觉和运动阻滞。",9.915166854858398,4.946056365966797,0.04728055000305176,0.4262869358062744,9.867886304855347,4.5197694301605225,claude-sonnet-4-5-20250929,True
盐酸甲哌卡因提供的麻醉通常能维持手术多长时间？,chinese,How long does the anesthesia provided by mepivacaine hydrochloride usually last during surgery?,". This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1 to 2 hours) reflects the sustained inactivation of the H + , K + ATPase. Table 3: Gastric Acid Parameters: ACIPHEX Delayed-Release Tablets versus Placebo After 7 Days of Once Daily Dosing Parameter ACIPHEX delayed-release tablets (20 mg once daily) Placebo Basal Acid Output (mmol/hr) 0.4* 2.8 Stimulated Acid Output (mmol/hr) 0.6* 13.3 % Time Gastric pH>3 65* 10 *(p<0.01 versus placebo) Compared to placebo, 10 mg, 20 mg, and 40 mg of ACIPHEX delayed-release tablets, administered once daily for 7 days significantly decreased intragastric acidity with all doses for each of four meal-related intervals and the 24-hour time period overall. In this study, there were no statistically significant differences between doses; however, there was a significant dose-related decrease in intragastric acidity

. This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1 to 2 hours) reflects the sustained inactivation of the H + , K + ATPase. Table 3: Gastric Acid Parameters: ACIPHEX Delayed-Release Tablets versus Placebo After 7 Days of Once Daily Dosing Parameter ACIPHEX delayed-release tablets (20 mg once daily) Placebo Basal Acid Output (mmol/hr) 0.4* 2.8 Stimulated Acid Output (mmol/hr) 0.6* 13.3 % Time Gastric pH>3 65* 10 *(p<0.01 versus placebo) Compared to placebo, 10 mg, 20 mg, and 40 mg of ACIPHEX delayed-release tablets, administered once daily for 7 days significantly decreased intragastric acidity with all doses for each of four meal-related intervals and the 24-hour time period overall. In this study, there were no statistically significant differences between doses; however, there was a significant dose-related decrease in intragastric acidity

. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great inter-patient variability. After oral administration, dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours. Duration of action for psychoactive effects is 4 to 6 hours, but the appetite stimulant effect of dronabinol may continue for 24 hours or longer after administration. Tachyphylaxis and tolerance develop to some of the pharmacologic effects of dronabinol with chronic use, suggesting an indirect effect on sympathetic neurons. In a study of the pharmacodynamics of chronic dronabinol exposure, healthy male subjects (N = 12) received 210 mg per day of dronabinol capsules, administered orally in divided doses, for 16 days. An initial tachycardia induced by dronabinol was replaced successively by normal sinus rhythm and then bradycardia. A decrease in supine blood pressure, made worse by standing, was also observed initially

. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great inter-patient variability. After oral administration, dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours. Duration of action for psychoactive effects is 4 to 6 hours, but the appetite stimulant effect of dronabinol may continue for 24 hours or longer after administration. Tachyphylaxis and tolerance develop to some of the pharmacologic effects of dronabinol with chronic use, suggesting an indirect effect on sympathetic neurons. In a study of the pharmacodynamics of chronic dronabinol exposure, healthy male subjects (N = 12) received 210 mg per day of dronabinol capsules, administered orally in divided doses, for 16 days. An initial tachycardia induced by dronabinol was replaced successively by normal sinus rhythm and then bradycardia. A decrease in supine blood pressure, made worse by standing, was also observed initially

. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great inter-patient variability. After oral administration, dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours. Duration of action for psychoactive effects is 4 to 6 hours, but the appetite stimulant effect of dronabinol may continue for 24 hours or longer after administration. Tachyphylaxis and tolerance develop to some of the pharmacologic effects of dronabinol with chronic use, suggesting an indirect effect on sympathetic neurons. In a study of the pharmacodynamics of chronic dronabinol exposure, healthy male subjects (N = 12) received 210 mg per day of dronabinol capsules, administered orally in divided doses, for 16 days. An initial tachycardia induced by dronabinol was replaced successively by normal sinus rhythm and then bradycardia. A decrease in supine blood pressure, made worse by standing, was also observed initially",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The duration of anesthesia also varies depending upon the technique and type of block, the concentration, and the individual. Mepivacaine will normally provide anesthesia which is adequate for 2 to 2 1 / 2 hours of surgery. Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma. Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by the degree of plasma protein binding, the degree of ionization, and the degree of lipid solubility. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer

. A dilute concentration of epinephrine (1:200,000 or 5 μ g/mL) usually reduces the rate of absorption and plasma concentration of mepivacaine, however, it has been reported that vasoconstrictors do not significantly prolong anesthesia with mepivacaine. Onset of anesthesia with mepivacaine is rapid, the time of onset for sensory block ranging from about 3 to 20 minutes depending upon such factors as the anesthetic technique, the type of block, the concentration of the solution, and the individual patient. The degree of motor blockade produced is dependent on the concentration of the solution. A 0.5% solution will be effective in small superficial nerve blocks while the 1% concentration will block sensory and sympathetic conduction without loss of motor function. The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group

INDICATIONS AND USAGE: 1.3 INDICATIONS AND USAGE 4% Lidocaine Hydrochloride Injection, USP is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the genito-urinary tract. It may be injected trans-tracheally to anesthetize the larynx and trachea, and it may be administered by retrobulbar injection to provide anesthesia for ophthalmic surgery.

INDICATIONS AND USAGE: 1.3 INDICATIONS AND USAGE 4% Lidocaine Hydrochloride Injection, USP is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the genito-urinary tract. It may be injected trans-tracheally to anesthetize the larynx and trachea, and it may be administered by retrobulbar injection to provide anesthesia for ophthalmic surgery.

INDICATIONS AND USAGE: 1.3 INDICATIONS AND USAGE 4% Lidocaine Hydrochloride Injection, USP is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the genito-urinary tract. It may be injected trans-tracheally to anesthetize the larynx and trachea, and it may be administered by retrobulbar injection to provide anesthesia for ophthalmic surgery.","Based on the medical information provided in English, I found no relevant information on the duration of anesthesia with Mepivacaine Hydrochloride.

The texts provided relate mainly to:
1. Gastric Acid Suppression of ACIPHEX (Rabeprazole) Delayed Release Tablets
2. Pharmacodynamic properties of Dronabinol

These contents have nothing to do with the anesthetic effects of mepivacaine hydrochloride. To find out the duration of anesthesia with mepivacaine hydrochloride, it is recommended to consult the specific instructions for this drug or consult a medical professional.","Based on the provided context, mepivacaine hydrochloride normally provides anesthesia that is adequate for **2 to 2½ hours of surgery**.

The context notes that the duration of anesthesia can vary depending on several factors including:
- The technique used
- The type of block
- The concentration of the solution
- Individual patient characteristics

However, the typical duration for surgical anesthesia is in the 2 to 2.5 hour range.",". This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1 to 2 hours) reflects the sustained inactivation of the H + , K + ATPase. Table 3: Gastric Acid Par
---
. This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1 to 2 hours) reflects the sustained inactivation of the H + , K + ATPase. Table 3: Gastric Acid Par
---
. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great inter-patient variability. After oral administration, dronabinol has an onset of action o
---
. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great inter-patient variability. After oral administration, dronabinol has an onset of action o
---
. These phenomena appear to be dose-related, increasing in frequency with higher dosages, and subject to great inter-patient variability. After oral administration, dronabinol has an onset of action o",". The 1.5% solution will provide extensive and often complete motor block and the 2% concentration of mepivacaine hydrochloride will produce complete sensory and motor block of any nerve group. The du
---
. A dilute concentration of epinephrine (1:200,000 or 5 μ g/mL) usually reduces the rate of absorption and plasma concentration of mepivacaine, however, it has been reported that vasoconstrictors do n
---
INDICATIONS AND USAGE: 1.3 INDICATIONS AND USAGE 4% Lidocaine Hydrochloride Injection, USP is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the
---
INDICATIONS AND USAGE: 1.3 INDICATIONS AND USAGE 4% Lidocaine Hydrochloride Injection, USP is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the
---
INDICATIONS AND USAGE: 1.3 INDICATIONS AND USAGE 4% Lidocaine Hydrochloride Injection, USP is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the",Healthcare assistant prompt,"根据提供的英文医疗信息内容，我没有找到关于盐酸甲哌卡因（Mepivacaine Hydrochloride）麻醉持续时间的相关信息。

提供的文本主要涉及：
1. ACIPHEX（雷贝拉唑）延迟释放片剂的胃酸抑制作用
2. 屈大麻酚（Dronabinol）的药效学特性

这些内容都与盐酸甲哌卡因的麻醉作用无关。如需了解盐酸甲哌卡因的麻醉持续时间，建议查阅该药物的专门说明书或咨询医疗专业人员。","根据所提供的情况，盐酸甲哌卡因通常提供足以**2 至 2.5 小时手术**的麻醉。

上下文指出，麻醉持续时间可能会因多种因素而异，包括：
- 使用的技术
- 块的类型
- 溶液的浓度
- 患者个体特征

然而，手术麻醉的典型持续时间为 2 至 2.5 小时。",6.628845930099487,6.2702014446258545,0.026487350463867188,0.4816884994506836,6.60235857963562,5.788512945175171,claude-sonnet-4-5-20250929,True
哌替啶盐酸盐注射液的pH范围是多少？,chinese,What is the pH range of pethidine hydrochloride injection?,". In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 µg), renal clearance was less than 2% of total plasma clearance. Drug Interactions FOSRENOL has a low potential for systemic drug-drug interactions because of the very low bioavailability of lanthanum and because it is not a substrate or inhibitor of major cytochrome P450 enzyme groups involved in drug metabolism (CYP1A2, CYP2C9/10, CYP2C19, CYP2D6 and CYP3A4/5). FOSRENOL does not alter gastric pH. Therefore, FOSRENOL drug interactions based on altered gastric pH are not expected. In an in vitro investigation, lanthanum did not form insoluble complexes when mixed in simulated gastric fluid with warfarin, digoxin, furosemide, phenytoin, metoprolol and enalapril

. In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 µg), renal clearance was less than 2% of total plasma clearance. Drug Interactions FOSRENOL has a low potential for systemic drug-drug interactions because of the very low bioavailability of lanthanum and because it is not a substrate or inhibitor of major cytochrome P450 enzyme groups involved in drug metabolism (CYP1A2, CYP2C9/10, CYP2C19, CYP2D6 and CYP3A4/5). FOSRENOL does not alter gastric pH. Therefore, FOSRENOL drug interactions based on altered gastric pH are not expected. In an in vitro investigation, lanthanum did not form insoluble complexes when mixed in simulated gastric fluid with warfarin, digoxin, furosemide, phenytoin, metoprolol and enalapril

. In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 µg), renal clearance was less than 2% of total plasma clearance. Drug Interactions FOSRENOL has a low potential for systemic drug-drug interactions because of the very low bioavailability of lanthanum and because it is not a substrate or inhibitor of major cytochrome P450 enzyme groups involved in drug metabolism (CYP1A2, CYP2C9/10, CYP2C19, CYP2D6 and CYP3A4/5). FOSRENOL does not alter gastric pH. Therefore, FOSRENOL drug interactions based on altered gastric pH are not expected. In an in vitro investigation, lanthanum did not form insoluble complexes when mixed in simulated gastric fluid with warfarin, digoxin, furosemide, phenytoin, metoprolol and enalapril

. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile solutions are clear and slightly yellow in color. image description

. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile solutions are clear and slightly yellow in color. image description",". Palonosetron Hydrochloride Injection is available as a 5 mL single-dose vial. Each 5 mL vial contains: 0.25 mg palonosetron (equivalent to 0.28 mg palonosetron HCl), 207.5 mg mannitol, disodium edetate and citrate buffer in water for intravenous administration. The pH of the solution in the 5 mL vial is 4.5 to 5.5. Figure

. Sertraline hydrochloride is supplied for oral administration as film-coated tablets containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingredients: D&C Yellow #10 (in 25 mg tablet), dibasic calcium phosphate anhydrous, FD&C Blue #1 (in 25 mg tablet), FD&C Blue #2 (in 50 mg tablet), FD&C Red #40 (in 25 mg tablet), hydroxypropyl cellulose, hypromellose, iron oxide yellow (in 100 mg tablet), magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Image 1

. The product is formulated at pH 5.2 and each 30 mL vial contains 300 mg of eculizumab-aeeb, sorbitol (E420) (1500 mg), acetic acid (18.0 mg), polysorbate 80 (3.0 mg) (vegetable origin), edetate disodium (EDTA) (0.6 mg), sodium hydroxide may be added to adjust pH, and Water for Injection, USP.

. The product is formulated at pH 5.2 and each 30 mL vial contains 300 mg of eculizumab-aeeb, sorbitol (E420) (1500 mg), acetic acid (18.0 mg), polysorbate 80 (3.0 mg) (vegetable origin), edetate disodium (EDTA) (0.6 mg), sodium hydroxide may be added to adjust pH, and Water for Injection, USP.

. The product is formulated at pH 5.2 and each 30 mL vial contains 300 mg of eculizumab-aeeb, sorbitol (E420) (1500 mg), acetic acid (18.0 mg), polysorbate 80 (3.0 mg) (vegetable origin), edetate disodium (EDTA) (0.6 mg), sodium hydroxide may be added to adjust pH, and Water for Injection, USP.","Based on the medical information provided in English, I was unable to find specific information about the pH range of Meperidine Hydrochloride Injection.

The text content provided mainly relates to:
1. Drug interaction information for FOSRENOL (lanthanum preparations)
2. A sterile solution containing 10% alcohol and sodium chloride with a pH range of 6.9-7.9

But none of this information is about pethidine hydrochloride injection.

Therefore, I cannot answer your question about the pH range of pethidine hydrochloride injection based on the English information currently available.","Based on the provided context, I cannot answer your question about the pH range of pethidine hydrochloride injection. The context does not contain any information about pethidine hydrochloride injection.

The context only includes information about:
- Palonosetron Hydrochloride Injection (pH 4.5 to 5.5)
- Sertraline hydrochloride tablets
- Eculizumab-aeeb injection (pH 5.2)

To obtain information about the pH range of pethidine hydrochloride injection, you would need to refer to different medical sources or product information specific to that medication.",". In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 µg), renal clearance was less than 2% of total plasma clearance. Drug Interactions FOSRENOL has a low poten
---
. In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 µg), renal clearance was less than 2% of total plasma clearance. Drug Interactions FOSRENOL has a low poten
---
. In healthy volunteers administered intravenous lanthanum as the soluble chloride salt (120 µg), renal clearance was less than 2% of total plasma clearance. Drug Interactions FOSRENOL has a low poten
---
. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile s
---
. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile s",". Palonosetron Hydrochloride Injection is available as a 5 mL single-dose vial. Each 5 mL vial contains: 0.25 mg palonosetron (equivalent to 0.28 mg palonosetron HCl), 207.5 mg mannitol, disodium edet
---
. Sertraline hydrochloride is supplied for oral administration as film-coated tablets containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingre
---
. The product is formulated at pH 5.2 and each 30 mL vial contains 300 mg of eculizumab-aeeb, sorbitol (E420) (1500 mg), acetic acid (18.0 mg), polysorbate 80 (3.0 mg) (vegetable origin), edetate diso
---
. The product is formulated at pH 5.2 and each 30 mL vial contains 300 mg of eculizumab-aeeb, sorbitol (E420) (1500 mg), acetic acid (18.0 mg), polysorbate 80 (3.0 mg) (vegetable origin), edetate diso
---
. The product is formulated at pH 5.2 and each 30 mL vial contains 300 mg of eculizumab-aeeb, sorbitol (E420) (1500 mg), acetic acid (18.0 mg), polysorbate 80 (3.0 mg) (vegetable origin), edetate diso",Healthcare assistant prompt,"根据提供的英文医疗信息,我无法找到关于哌替啶盐酸盐注射液(Meperidine Hydrochloride Injection)pH范围的具体信息。

提供的文本内容主要涉及:
1. FOSRENOL(镧制剂)的药物相互作用信息
2. 某种含有10%酒精和氯化钠的无菌溶液,其pH范围为6.9-7.9

但这些信息都不是关于哌替啶盐酸盐注射液的。

因此,我无法根据当前提供的英文资料回答您关于哌替啶盐酸盐注射液pH范围的问题。","根据您提供的情况，我无法回答您关于盐酸哌替啶注射液pH范围的问题。上下文中不包含任何有关盐酸哌替啶注射液的信息。

上下文仅包含以下信息：
- 盐酸帕洛诺司琼注射液（pH 4.5至5.5）
- 盐酸舍曲林片
- Eculizumab-aeeb注射液（pH 5.2）

要获取有关盐酸哌替啶注射液 pH 范围的信息，您需要参考不同的医疗来源或特定于该药物的产品信息。",8.069742918014526,6.282372951507568,0.03292083740234375,0.4598860740661621,8.036822080612183,5.822486877441406,claude-sonnet-4-5-20250929,True
哌替啶盐酸盐注射液有哪些给药形式？,chinese,What are the administration forms of pethidine hydrochloride injection?,"CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.",". 2.2 Instructions for Intravenous Administration Palonosetron hydrochloride injection is supplied ready for intravenous administration at a concentration of 0.05 mg per mL (50 mcg per mL). Do not mix palonosetron hydrochloride injection with other drugs. Flush the infusion line with normal saline before and after administration of palonosetron hydrochloride injection. Inspect palonosetron hydrochloride injection visually for particulate matter and discoloration before administration. Discard unused portion.

DESCRIPTION: 11 DESCRIPTION Palonosetron hydrochloride injection contains palonosetron as palonosetron HCl, an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT 3 ) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3a S )-2-[( S )-1-Azabicyclo [2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1 H benz[ de ]isoquinoline hydrochloride. The empirical formula is C 19 H 24 N 2 O.HCl, with a molecular weight of 332.87. Palonosetron hydrochloride exists as a single isomer and has the following structural formula: Palonosetron hydrochloride is a white to off-white crystalline powder. It is freely soluble in water, soluble in propylene glycol, and slightly soluble in ethanol and 2-propanol. Palonosetron hydrochloride injection is a sterile, clear, colorless, non-pyrogenic, isotonic, buffered solution for intravenous administration. Palonosetron Hydrochloride Injection is available as a 5 mL single-dose vial

. Corticosteroids, Analgesics, Antiemetics/Antinauseants, Antispasmodics and Anticholinergic Agents In controlled clinical trials, palonosetron hydrochloride injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents.

. Sertraline hydrochloride is supplied for oral administration as film-coated tablets containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingredients: D&C Yellow #10 (in 25 mg tablet), dibasic calcium phosphate anhydrous, FD&C Blue #1 (in 25 mg tablet), FD&C Blue #2 (in 50 mg tablet), FD&C Red #40 (in 25 mg tablet), hydroxypropyl cellulose, hypromellose, iron oxide yellow (in 100 mg tablet), magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Image 1

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is a combination of the β ​2 -adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium bromide. Albuterol sulfate: Mechanism of Action: ​ The prime action of β-adrenergic drugs is to stimulate adenyl cyclase, the enzyme that catalyzes the formation of cyclic-3’,5’-adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). The cAMP thus formed mediates the cellular responses. In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on β ​2 -adrenergic receptors compared with isoproterenol. While it is recognized that β ​2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, recent data indicated that 10% to 50% of the β-receptors in the human heart may be β ​2 -receptors. The precise function of these receptors, however, is not yet established","Based on the medical information provided, I was unable to find information regarding the dosing form of pethidine hydrochloride injection.

The text provided deals only with clinical pharmacology information on glucocorticoids (such as hydrocortisone and cortisone) and does not contain any information on pethidine hydrochloride injection.

To learn about the administration form of pethidine hydrochloride injection, it is recommended to consult the specific instructions for the drug or consult a medical professional.","Based on the provided context, I cannot answer your question about pethidine hydrochloride injection. The context provided contains information about:

1. Palonosetron hydrochloride injection (an antiemetic)
2. Sertraline hydrochloride tablets (an oral medication)
3. Ipratropium Bromide and Albuterol Sulfate Inhalation Solution (a bronchodilator)

There is no information about pethidine hydrochloride injection in the provided medical sources. To answer your question accurately, I would need context that specifically discusses pethidine hydrochloride (also known as meperidine) and its administration forms.","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor",". 2.2 Instructions for Intravenous Administration Palonosetron hydrochloride injection is supplied ready for intravenous administration at a concentration of 0.05 mg per mL (50 mcg per mL). Do not mix
---
DESCRIPTION: 11 DESCRIPTION Palonosetron hydrochloride injection contains palonosetron as palonosetron HCl, an antiemetic and antinauseant agent. It is a serotonin-3 (5-HT 3 ) receptor antagonist with
---
. Corticosteroids, Analgesics, Antiemetics/Antinauseants, Antispasmodics and Anticholinergic Agents In controlled clinical trials, palonosetron hydrochloride injection has been safely administered wit
---
. Sertraline hydrochloride is supplied for oral administration as film-coated tablets containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingre
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Ipratropium Bromide and Albuterol Sulfate Inhalation Solution is a combination of the β ​2 -adrenergic bronchodilator, albuterol sulfate, and the anticholi",Healthcare assistant prompt,"根据提供的医疗信息内容，我无法找到关于哌替啶盐酸盐注射液给药形式的相关信息。

提供的文本内容仅涉及糖皮质激素（如氢化可的松和可的松）的临床药理学信息，并未包含哌替啶盐酸盐注射液的任何信息。

如需了解哌替啶盐酸盐注射液的给药形式，建议查阅该药物的专门说明书或咨询医疗专业人员。","根据您提供的情况，我无法回答您关于盐酸哌替啶注射液的问题。提供的上下文包含以下信息：

1.盐酸帕洛诺司琼注射液（止吐药）
2.盐酸舍曲林片（口服药物）
3.异丙托溴铵硫酸沙丁胺醇吸入溶液（支气管扩张剂）

所提供的医疗来源中没有关于盐酸哌替啶注射液的信息。为了准确回答您的问题，我需要专门讨论盐酸哌替啶（也称为哌替啶）及其给药形式的上下文。",6.43752384185791,6.328850507736206,0.023900747299194336,0.6043062210083008,6.413623094558716,5.724544286727905,claude-sonnet-4-5-20250929,True
哌替啶盐酸盐的熔点是多少？,chinese,What is the melting point of pethidine hydrochloride?,". Sulfuric acid and, if necessary, sodium hydroxide may be added to adjust pH (4.0 – 5.5). Preservative: benzalkonium chloride 0.004% Trimethoprim sulfate (Structural formula) Polymyxin B Sulfate, the sulfate salt of polymyxin B1 and B2 (Structural formula)

. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile solutions are clear and slightly yellow in color. image description

. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile solutions are clear and slightly yellow in color. image description

. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry flavor and odor. Other ingredients: citric acid, FD&C Red #40, D&C Red #33, raspberry flavor, glycerin, methylparaben, sodium benzoate, sodium saccharin, xanthan gum, and purified water.

. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry flavor and odor. Other ingredients: citric acid, FD&C Red #40, D&C Red #33, raspberry flavor, glycerin, methylparaben, sodium benzoate, sodium saccharin, xanthan gum, and purified water.","DESCRIPTION: DESCRIPTION Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt with the empirical formula C20H21N • HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride. Each tablet contains the following inactive ingredients: croscarmellose sodium, FD&C Yellow #6, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide; 5 mg tablets also contain FD&C Red #40 and 10 mg tablets contain D&C Yellow #10 and polysorbate.

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, pregelatinized starch (corn), sodium lauryl sulfate, titanium dioxide and triacetin. The 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg and 320 mg/12.5 mg tablets also contain red iron oxide and yellow iron oxide. The 320 mg/25 mg tablet also contains FD&C Blue No. 2 Aluminum Lake and FD&C Yellow No

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, pregelatinized starch (corn), sodium lauryl sulfate, titanium dioxide and triacetin. The 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg and 320 mg/12.5 mg tablets also contain red iron oxide and yellow iron oxide. The 320 mg/25 mg tablet also contains FD&C Blue No. 2 Aluminum Lake and FD&C Yellow No

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, pregelatinized starch (corn), sodium lauryl sulfate, titanium dioxide and triacetin. The 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg and 320 mg/12.5 mg tablets also contain red iron oxide and yellow iron oxide. The 320 mg/25 mg tablet also contains FD&C Blue No. 2 Aluminum Lake and FD&C Yellow No

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below","Based on the medical information provided, I found no relevant information on the melting point of Meperidine Hydrochloride.

The content provided mainly involves:
- Ophthalmic preparations containing trimethoprim and polymyxin B
- Sterile solution containing alcohol and sodium chloride
- Antihistamine suspension containing pyrilamine tannins

None of this information relates to pethidine hydrochloride. For information on the melting point of pethidine hydrochloride, it is recommended to consult the specific product insert or pharmacopeia information for the drug.","Based on the provided context, I cannot answer your question about the melting point of pethidine hydrochloride. The context only contains information about cyclobenzaprine hydrochloride (which has a melting point of 217°C) and hydrochlorothiazide, but does not include any information about pethidine hydrochloride.",". Sulfuric acid and, if necessary, sodium hydroxide may be added to adjust pH (4.0 – 5.5). Preservative: benzalkonium chloride 0.004% Trimethoprim sulfate (Structural formula) Polymyxin B Sulfate, the
---
. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile s
---
. The solutions contain 10% (w/v) alcohol,USP, and 8.70 mg of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile s
---
. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry f
---
. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry f","DESCRIPTION: DESCRIPTION Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt with the empirical formula C20H21N • HCl and a molecular weight of 311.9. It has a melting point of 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H ",Healthcare assistant prompt,"根据提供的医疗信息内容，我没有找到关于哌替啶盐酸盐（Meperidine Hydrochloride）熔点的相关信息。

提供的内容主要涉及：
- 含有三甲氧苄氨嘧啶和多粘菌素B的眼科制剂
- 含有酒精和氯化钠的无菌溶液
- 含有吡拉明丹宁酸盐的抗组胺药物悬浮液

这些信息都与哌替啶盐酸盐无关。如需了解哌替啶盐酸盐的熔点信息，建议查阅该药物的具体产品说明书或药典资料。",根据所提供的情况，我无法回答你关于盐酸哌替啶熔点的问题。上下文仅包含有关盐酸环苯扎林（熔点为 217°C）和氢氯噻嗪的信息，但不包含有关盐酸哌替啶的任何信息。,8.427906274795532,4.9405717849731445,0.028189420700073242,0.42767810821533203,8.399716854095459,4.5128936767578125,claude-sonnet-4-5-20250929,True
盐酸哌替啶的化学成分是什么？,chinese,What is the chemical composition of pethidine hydrochloride?,". Sulfuric acid and, if necessary, sodium hydroxide may be added to adjust pH (4.0 – 5.5). Preservative: benzalkonium chloride 0.004% Trimethoprim sulfate (Structural formula) Polymyxin B Sulfate, the sulfate salt of polymyxin B1 and B2 (Structural formula)

. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry flavor and odor. Other ingredients: citric acid, FD&C Red #40, D&C Red #33, raspberry flavor, glycerin, methylparaben, sodium benzoate, sodium saccharin, xanthan gum, and purified water.

. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry flavor and odor. Other ingredients: citric acid, FD&C Red #40, D&C Red #33, raspberry flavor, glycerin, methylparaben, sodium benzoate, sodium saccharin, xanthan gum, and purified water.

DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure: Divalproex sodium, USP occurs as a white crystalline powder with a characteristic odor. Divalproex sodium extended-release 250 and 500 mg tablets are for oral administration. Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid

DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure: Divalproex sodium, USP occurs as a white crystalline powder with a characteristic odor. Divalproex sodium extended-release 250 and 500 mg tablets are for oral administration. Divalproex sodium extended-release tablets, USP contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 or 500 mg of valproic acid",". Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets USP are formulated for oral administration to contain valsartan and hydrochlorothiazide, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, croscarmellose sodium, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, titanium dioxide and additional colorants as below

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, pregelatinized starch (corn), sodium lauryl sulfate, titanium dioxide and triacetin. The 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg and 320 mg/12.5 mg tablets also contain red iron oxide and yellow iron oxide. The 320 mg/25 mg tablet also contains FD&C Blue No. 2 Aluminum Lake and FD&C Yellow No

. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 8 ClN 3 O 4 S 2 , its molecular weight is 297.73, and its structural formula is Valsartan and hydrochlorothiazide tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg and 320 mg/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, pregelatinized starch (corn), sodium lauryl sulfate, titanium dioxide and triacetin. The 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg and 320 mg/12.5 mg tablets also contain red iron oxide and yellow iron oxide. The 320 mg/25 mg tablet also contains FD&C Blue No. 2 Aluminum Lake and FD&C Yellow No","According to the English medical information provided, I did not find any relevant information about the chemical composition of Meperidine Hydrochloride/Pethidine Hydrochloride.

The document content provided mainly involves:
- Trimethoprim sulfate and polymyxin B sulfate
- Pyrilamine tannin (Chlor-Tan A 12)
- Divalproex sodium

None of these drugs are related to pethidine hydrochloride. If you want to know the chemical composition information of pethidine hydrochloride, it is recommended to consult the special instructions or pharmacopoeia information of the drug.","Based on the provided context, I cannot answer your question about the chemical composition of pethidine hydrochloride. The context only contains information about hydrochlorothiazide and valsartan/hydrochlorothiazide combination tablets. There is no information about pethidine hydrochloride in the provided medical sources.

To get accurate information about pethidine hydrochloride's chemical composition, you would need to consult different FDA or NIH sources that specifically cover that medication.",". Sulfuric acid and, if necessary, sodium hydroxide may be added to adjust pH (4.0 – 5.5). Preservative: benzalkonium chloride 0.004% Trimethoprim sulfate (Structural formula) Polymyxin B Sulfate, the
---
. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry f
---
. The tannate salt of pyrilamine has the empirical formula C 93 H 75 N 3 0 47 and MW = 1986.28. Chlor-Tan A 12 is a decongestant antihistamine suspension, which is red/pink in color with a raspberry f
---
DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralizatio
---
DESCRIPTION: 11 DESCRIPTION Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralizatio",". Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H 
---
. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Hydrochlorothiazide is a thiazide diuretic. Its molecular formula is C 7 H ",Healthcare assistant prompt,"根据提供的英文医疗信息内容,我没有找到关于盐酸哌替啶(Meperidine Hydrochloride/Pethidine Hydrochloride)化学成分的相关信息。

提供的文档内容主要涉及:
- 硫酸三甲氧苄氨嘧啶和多粘菌素B硫酸盐
- 吡拉明单宁酸盐(Chlor-Tan A 12)
- 双丙戊酸钠(Divalproex sodium)

这些药物都与盐酸哌替啶无关。如需了解盐酸哌替啶的化学成分信息,建议查阅该药物的专门说明书或药典资料。","根据您提供的情况，我无法回答您有关盐酸哌替啶化学成分的问题。上下文仅包含有关氢氯噻嗪和缬沙坦/氢氯噻嗪组合片的信息。所提供的医疗来源中没有有关盐酸哌替啶的信息。

要获得有关盐酸哌替啶化学成分的准确信息，您需要咨询专门涵盖该药物的不同 FDA 或 NIH 来源。",7.63240122795105,5.94218373298645,0.02501201629638672,0.5409619808197021,7.607389211654663,5.401221752166748,claude-sonnet-4-5-20250929,True
盐酸哌替啶作为麻醉性镇痛药的作用是什么？,chinese,What is the role of pethidine hydrochloride as a narcotic analgesic?,"CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically, this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve the central nervous system and smooth muscle. The precise mechanism of action of hydrocodone and other opiates is not known, although it is believed to relate to the existence of opiate receptors in the central nervous system. In addition to analgesia, narcotics may produce drowsiness, changes in mood and mental clouding. The analgesic action of acetaminophen involves peripheral influences, but the specific mechanism is as yet undetermined. Antipyretic activity is mediated through hypothalamic heat regulating centers. Acetaminophen inhibits prostaglandin synthetase. Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing

CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve the central nervous system and smooth muscle. The precise mechanism of action of hydrocodone and other opiates is not known, although it is believed to relate to the existence of opiate receptors in the central nervous system. In addition to analgesia, narcotics may produce drowsiness, changes in mood and mental clouding. The analgesic action of acetaminophen involves peripheral influences, but the specific mechanism is as yet undetermined. Antipyretic activity is mediated through hypothalamic heat regulating centers. Acetaminophen inhibits prostaglandin synthetase. Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing

CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tramadol hydrochloride tablets contain tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. Although the mode of action is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to µ-opioid receptors and weak inhibition of re- uptake of norepinephrine and serotonin. Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O -demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in µ opioid binding. Tramadol-induced analgesia is only partially antagonized by the opioid antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human analgesia is dependent upon the plasma concentrations of each compound [see Clinical Pharmacology (12.2)]

CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tramadol hydrochloride tablets contain tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. Although the mode of action is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to µ-opioid receptors and weak inhibition of re- uptake of norepinephrine and serotonin. Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O -demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in µ opioid binding. Tramadol-induced analgesia is only partially antagonized by the opioid antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human analgesia is dependent upon the plasma concentrations of each compound [see Clinical Pharmacology (12.2)]","Based on the medical information provided, I cannot answer your question about meperidine hydrochloride.

The contextual content provided relates only to clinical pharmacology information of glucocorticoids (e.g., hydrocortisone and cortisone), including their anti-inflammatory effects, alternative therapeutic uses, and effects on metabolism and the immune system.

The article does not contain any information about pethidine hydrochloride, a narcotic analgesic.

To understand the mechanism of action and clinical uses of pethidine hydrochloride, it is recommended to consult medical information specific to this drug.","Based on the provided context, there is no information about pethidine hydrochloride. The context discusses other medications including:

1. **Amitriptyline hydrochloride** - an antidepressant
2. **Hydrocodone** - a semisynthetic narcotic analgesic
3. **Tramadol** - an opioid agonist and analgesic

None of these sections contain information about pethidine hydrochloride (also known as meperidine), so I cannot answer your question based on the provided medical sources.

If you need information about pethidine hydrochloride specifically, you would need to provide relevant FDA or NIH documentation that discusses this particular medication.","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocor","CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibito
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve th
---
CLINICAL PHARMACOLOGY: CLINICAL PHARMACOLOGY Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve th
---
CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tramadol hydrochloride tablets contain tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. Al
---
CLINICAL PHARMACOLOGY: 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tramadol hydrochloride tablets contain tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re- uptake. Al",Healthcare assistant prompt,"根据提供的医学信息，我无法回答关于盐酸哌替啶（meperidine hydrochloride）的问题。

提供的上下文内容仅涉及糖皮质激素（如氢化可的松和可的松）的临床药理学信息，包括它们的抗炎作用、替代治疗用途以及对代谢和免疫系统的影响。

文中没有包含任何关于盐酸哌替啶这种麻醉性镇痛药的信息。

如需了解盐酸哌替啶的作用机制和临床用途，建议查阅专门针对该药物的医学资料。","根据所提供的情况，没有关于盐酸哌替啶的信息。上下文讨论了其他药物，包括：

1. **盐酸阿米替林** - 一种抗抑郁药
2. **氢可酮** - 一种半合成麻醉镇痛药
3. **曲马多** - 一种阿片类激动剂和镇痛药

这些部分均不包含有关盐酸哌替啶（也称为哌替啶）的信息，因此我无法根据提供的医疗来源回答您的问题。

如果您需要具体了解盐酸哌替啶的信息，您需要提供讨论这种特定药物的相关 FDA 或 NIH 文件。",7.3742454051971436,6.489883661270142,0.029392242431640625,0.5785031318664551,7.344853162765503,5.9113805294036865,claude-sonnet-4-5-20250929,True
盐酸哌替啶注射液有哪些浓度可用？,chinese,What concentrations of pethidine hydrochloride injection are available?,". 12.3 Pharmacokinetics Absorption/Bioavailability Equivalent oral doses of divalproex sodium products and valproic acid capsules deliver equivalent quantities of valproate ion systemically. Although the rate of valproate ion absorption may vary with the formulation administered (liquid, solid, or sprinkle), conditions of use (e.g., fasting or postprandial) and the method of administration (e.g., whether the contents of the capsule are sprinkled on food or the capsule is taken intact), these differences should be of minor clinical importance under the steady state conditions achieved in chronic use in the treatment of epilepsy. However, it is possible that differences among the various valproate products in T max and C max could be important upon initiation of treatment

. 12.3 Pharmacokinetics Absorption/Bioavailability Equivalent oral doses of divalproex sodium products and valproic acid capsules deliver equivalent quantities of valproate ion systemically. Although the rate of valproate ion absorption may vary with the formulation administered (liquid, solid, or sprinkle), conditions of use (e.g., fasting or postprandial) and the method of administration (e.g., whether the contents of the capsule are sprinkled on food or the capsule is taken intact), these differences should be of minor clinical importance under the steady state conditions achieved in chronic use in the treatment of epilepsy. However, it is possible that differences among the various valproate products in T max and C max could be important upon initiation of treatment

. 12.3 Pharmacokinetics Absorption/Bioavailability Equivalent oral doses of divalproex sodium products and valproic acid capsules deliver equivalent quantities of valproate ion systemically. Although the rate of valproate ion absorption may vary with the formulation administered (liquid, solid, or sprinkle), conditions of use (e.g., fasting or postprandial) and the method of administration (e.g., whether the contents of the capsule are sprinkled on food or the capsule is taken intact), these differences should be of minor clinical importance under the steady state conditions achieved in chronic use in the treatment of epilepsy. However, it is possible that differences among the various valproate products in T max and C max could be important upon initiation of treatment

. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt intake should be carefully monitored in order to avoid the development of hypertension, edema or weight gain. Periodic checking of serum electrolyte levels is advisable during prolonged therapy; dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Patients should not be vaccinated against smallpox while on corticosteroid therapy. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response

. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt intake should be carefully monitored in order to avoid the development of hypertension, edema or weight gain. Periodic checking of serum electrolyte levels is advisable during prolonged therapy; dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Patients should not be vaccinated against smallpox while on corticosteroid therapy. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response",". Palonosetron Hydrochloride Injection is available as a 5 mL single-dose vial. Each 5 mL vial contains: 0.25 mg palonosetron (equivalent to 0.28 mg palonosetron HCl), 207.5 mg mannitol, disodium edetate and citrate buffer in water for intravenous administration. The pH of the solution in the 5 mL vial is 4.5 to 5.5. Figure

. 2.2 Instructions for Intravenous Administration Palonosetron hydrochloride injection is supplied ready for intravenous administration at a concentration of 0.05 mg per mL (50 mcg per mL). Do not mix palonosetron hydrochloride injection with other drugs. Flush the infusion line with normal saline before and after administration of palonosetron hydrochloride injection. Inspect palonosetron hydrochloride injection visually for particulate matter and discoloration before administration. Discard unused portion.

. Sertraline hydrochloride is supplied for oral administration as film-coated tablets containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingredients: D&C Yellow #10 (in 25 mg tablet), dibasic calcium phosphate anhydrous, FD&C Blue #1 (in 25 mg tablet), FD&C Blue #2 (in 50 mg tablet), FD&C Red #40 (in 25 mg tablet), hydroxypropyl cellulose, hypromellose, iron oxide yellow (in 100 mg tablet), magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate and titanium dioxide. Image 1

. Solutions which are discolored or which contain particulate matter should not be administered. Recommended Concentrations and Doses of Mepivacaine Hydrochloride Procedure Concentration Total Dose Comments mL mg Cervical, brachial, intercostal, 1% 5−40 50−400 Pudendal block: one half of total dose injected each side. pudendal nerve block 2% 5−20 100−400 Transvaginal block (paracervical plus pudendal) 1% up to 30 (both sides) up to 300 (both sides) One half of total dose injected each side. See PRECAUTIONS . Paracervical block 1% up to 20 (both sides) up to 200 (both sides) One half of total dose injected each side. This is maximum recommended dose per 90-minute period in obstetrical and non-obstetrical patients. Inject slowly, 5 minutes between sides. See PRECAUTIONS . Caudal and Epidural block 1% 1.5% 15−30 10−25 150−300 150−375 Dosage forms listed as POLOCAINE-MPF (Mepivacaine HCl injection, USP) are single-dose solutions which do not contain a preservative

. Each single-dose vial, formulated in an aqueous solution, is available at a concentration of 20 mg/mL containing 80 mg/4 mL, 200 mg/10 mL, or 400 mg/20 mL of TOFIDENCE. Each mL of solution contains arginine hydrochloride (10.53 mg), histidine (0.81 mg), L-histidine hydrochloride monohydrate (1.01 mg), polysorbate 80 (0.5 mg), sucrose (20 mg), and water for injection.","Based on the medical information provided in English, I was unable to find information on the concentration of Meperidine Hydrochloride Injection.

The text content provided mainly relates to:
1. Pharmacokinetic information of divalproex sodium and valproic acid
2. Precautions for use of fludrocortisone acetate

These are not relevant to pethidine hydrochloride injection and therefore do not answer your question about its available concentrations.","Based on the provided context, there is no information about pethidine hydrochloride injection or its available concentrations. The context contains information about other medications including:

- Palonosetron Hydrochloride Injection (0.05 mg per mL)
- Sertraline hydrochloride tablets
- Mepivacaine Hydrochloride (1%, 1.5%, and 2% concentrations)
- TOFIDENCE (20 mg/mL)

To answer your question about pethidine hydrochloride injection concentrations, I would need access to relevant medical information specifically about that medication.",". 12.3 Pharmacokinetics Absorption/Bioavailability Equivalent oral doses of divalproex sodium products and valproic acid capsules deliver equivalent quantities of valproate ion systemically. Although 
---
. 12.3 Pharmacokinetics Absorption/Bioavailability Equivalent oral doses of divalproex sodium products and valproic acid capsules deliver equivalent quantities of valproate ion systemically. Although 
---
. 12.3 Pharmacokinetics Absorption/Bioavailability Equivalent oral doses of divalproex sodium products and valproic acid capsules deliver equivalent quantities of valproate ion systemically. Although 
---
. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt 
---
. These effects are less likely to occur with the synthetic derivatives except when used in large doses. However, since fludrocortisone acetate is a potent mineralocorticoid, both the dosage and salt ",". Palonosetron Hydrochloride Injection is available as a 5 mL single-dose vial. Each 5 mL vial contains: 0.25 mg palonosetron (equivalent to 0.28 mg palonosetron HCl), 207.5 mg mannitol, disodium edet
---
. 2.2 Instructions for Intravenous Administration Palonosetron hydrochloride injection is supplied ready for intravenous administration at a concentration of 0.05 mg per mL (50 mcg per mL). Do not mix
---
. Sertraline hydrochloride is supplied for oral administration as film-coated tablets containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingre
---
. Solutions which are discolored or which contain particulate matter should not be administered. Recommended Concentrations and Doses of Mepivacaine Hydrochloride Procedure Concentration Total Dose Co
---
. Each single-dose vial, formulated in an aqueous solution, is available at a concentration of 20 mg/mL containing 80 mg/4 mL, 200 mg/10 mL, or 400 mg/20 mL of TOFIDENCE. Each mL of solution contains ",Healthcare assistant prompt,"根据提供的英文医疗信息内容，我无法找到关于盐酸哌替啶注射液（Meperidine Hydrochloride Injection）浓度的相关信息。

提供的文本内容主要涉及：
1. 双丙戊酸钠和丙戊酸的药代动力学信息
2. 氟氢可的松醋酸酯的使用注意事项

这些内容与盐酸哌替啶注射液无关，因此无法回答您关于其可用浓度的问题。","根据所提供的情况，没有关于盐酸哌替啶注射液或其可用浓度的信息。上下文包含有关其他药物的信息，包括：

- 盐酸帕洛诺司琼注射液（0.05 mg/mL）
- 盐酸舍曲林片
- 盐酸甲哌卡因（1%、1.5% 和 2% 浓度）
- 托菲登斯 (20 毫克/毫升)

为了回答您有关盐酸哌替啶注射液浓度的问题，我需要获取专门关于该药物的相关医疗信息。",24.76193857192993,6.685022592544556,0.038251638412475586,0.5036664009094238,24.723686933517456,6.181356191635132,claude-sonnet-4-5-20250929,True
血浆浓度与局部麻醉药物结合之间的关系是什么？,chinese,What is the relationship between plasma concentrations and local anesthetic drug binding?,". At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block and ultimately to cardiac arrest. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression, or both. Apparent central stimulation is manifested as restlessness, tremors, and shivering, progressing to convulsions, followed by depression and coma progressing ultimately to respiratory arrest. However, the local anesthetics have a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited stage

. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacaine is approximately 75% bound to plasma proteins. The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation. Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain. Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or renal disease, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient

. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the increased risk of bleeding associated with the concomitant use of paroxetine and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio. 5.6 Activation of Mania or Hypomania In patients with bipolar disorder, treating a depressive episode with paroxetine tablet or another antidepressant may precipitate a mixed/manic episode. During controlled clinical trials of paroxetine, hypomania or mania occurred in approximately 1% of paroxetine-treated unipolar patients compared to 1.1% of active-control and 0.3% of placebo-treated unipolar patients. Prior to initiating treatment with paroxetine, screen patients for any personal or family history of bipolar disorder, mania, or hypomania

. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the increased risk of bleeding associated with the concomitant use of paroxetine and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio. 5.6 Activation of Mania or Hypomania In patients with bipolar disorder, treating a depressive episode with paroxetine tablet or another antidepressant may precipitate a mixed/manic episode. During controlled clinical trials of paroxetine, hypomania or mania occurred in approximately 1% of paroxetine-treated unipolar patients compared to 1.1% of active-control and 0.3% of placebo-treated unipolar patients. Prior to initiating treatment with paroxetine, screen patients for any personal or family history of bipolar disorder, mania, or hypomania

. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the increased risk of bleeding associated with the concomitant use of paroxetine and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio. 5.6 Activation of Mania or Hypomania In patients with bipolar disorder, treating a depressive episode with paroxetine tablet or another antidepressant may precipitate a mixed/manic episode. During controlled clinical trials of paroxetine, hypomania or mania occurred in approximately 1% of paroxetine-treated unipolar patients compared to 1.1% of active-control and 0.3% of placebo-treated unipolar patients. Prior to initiating treatment with paroxetine, screen patients for any personal or family history of bipolar disorder, mania, or hypomania",". Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacaine is approximately 75% bound to plasma proteins. The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation. Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain. Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or renal disease, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient

DOSAGE AND ADMINISTRATION: DOSAGE AND ADMINISTRATION The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance and the physical condition of the patient. The smallest dose and concentration required to produce the desired result should be administered. Dosages of mepivacaine hydrochloride should be reduced for elderly and debilitated patients and patients with cardiac and/or liver disease. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional doses should be used when feasible. For specific techniques and procedures, refer to standard textbooks

. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4′-N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations observed. Direct glucuronidation and cytochrome P450 (CYP) mediated oxidation are the primary metabolic pathways for olanzapine. In vitro studies suggest that CYPs 1A2 and 2D6, and the flavin-containing monooxygenase system are involved in olanzapine oxidation. CYP2D6 mediated oxidation appears to be a minor metabolic pathway in vivo, because the clearance of olanzapine is not reduced in subjects who are deficient in this enzyme

. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4′-N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations observed. Direct glucuronidation and cytochrome P450 (CYP) mediated oxidation are the primary metabolic pathways for olanzapine. In vitro studies suggest that CYPs 1A2 and 2D6, and the flavin-containing monooxygenase system are involved in olanzapine oxidation. CYP2D6 mediated oxidation appears to be a minor metabolic pathway in vivo, because the clearance of olanzapine is not reduced in subjects who are deficient in this enzyme

. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4′-N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations observed. Direct glucuronidation and cytochrome P450 (CYP) mediated oxidation are the primary metabolic pathways for olanzapine. In vitro studies suggest that CYPs 1A2 and 2D6, and the flavin-containing monooxygenase system are involved in olanzapine oxidation. CYP2D6 mediated oxidation appears to be a minor metabolic pathway in vivo, because the clearance of olanzapine is not reduced in subjects who are deficient in this enzyme","According to the medical information provided, there is an **inverse relationship** between the extent to which local anesthetic drugs bind to plasma proteins and their fetal/maternal ratio.

Specifically:

1. **Only free, unbound drugs can be transferred across the placenta**

2. **The higher the plasma protein binding rate, the less placental transfer**
   - For example: Mepivacaine is approximately 75% bound to plasma proteins

3. **Other factors affecting placental transfer include:**
   - Degree of ionization of the drug
   - Lipid-soluble (fat-soluble, non-ionized drugs are more likely to pass from the maternal circulation into the fetal blood)

4. **Drug distribution characteristics:**
   -Local anesthetic is distributed to some extent to all body tissues
   - Higher concentrations in highly perfused organs such as liver, lungs, heart and brain

In short, ** local anesthetics with higher plasma protein binding rates will have lower free drug concentrations and less transfer across the placenta**.","Based on the provided context, the relationship between plasma concentrations and local anesthetic drug binding is as follows:

**Plasma protein binding affects placental transfer**: The context specifically states that ""Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer.""

This means:
- Only the **free (unbound) portion** of the local anesthetic in plasma can cross the placenta
- The **higher the plasma protein binding**, the **less drug is available** for placental transfer
- For mepivacaine specifically, approximately **75% is bound to plasma proteins**, leaving only 25% free and available for transfer

In summary, plasma protein binding directly determines how much local anesthetic remains free in the plasma and available for distribution across biological membranes, including the placenta. The bound portion stays in the maternal circulation and cannot transfer to the fetus.",". At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, t
---
. Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacain
---
. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the in
---
. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the in
---
. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the in",". Fetal/maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Mepivacain
---
DOSAGE AND ADMINISTRATION: DOSAGE AND ADMINISTRATION The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, th
---
. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the
---
. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the
---
. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the",Healthcare assistant prompt,"根据提供的医学信息，局部麻醉药物与血浆蛋白的结合程度与其胎儿/母体比率呈**反比关系**。

具体来说：

1. **只有游离的、未结合的药物才能通过胎盘转移**

2. **血浆蛋白结合率越高，胎盘转移越少**
   - 例如：美哌卡因（Mepivacaine）约有75%与血浆蛋白结合

3. **影响胎盘转移的其他因素包括：**
   - 药物的离子化程度
   - 脂溶性（脂溶性、非离子化的药物更容易从母体循环进入胎儿血液）

4. **药物分布特点：**
   - 局部麻醉药在一定程度上分布到所有身体组织
   - 在高灌注器官（如肝脏、肺、心脏和大脑）中浓度较高

简而言之，**血浆蛋白结合率越高的局部麻醉药，其游离药物浓度越低，通过胎盘转移的量也越少**。","根据所提供的情况，血浆浓度与局麻药结合之间的关系如下：

**血浆蛋白结合影响胎盘转移**：上下文特别指出“局部麻醉剂的胎儿/母体比例似乎与血浆蛋白结合程度成反比，因为只有游离的、未结合的药物可用于胎盘转移。”

这意味着：
- 只有血浆中局麻药的**游离（未结合）部分**可以穿过胎盘
- **血浆蛋白结合越高**，**可用于胎盘移植的药物就越少**
- 特别是对于甲哌卡因，大约 **75% 与血浆蛋白结合**，仅留下 25% 游离并可用于转移

总之，血浆蛋白结合直接决定有多少局部麻醉剂在血浆中保持游离状态并可跨生物膜（包括胎盘）分布。结合的部分留在母体循环中，不能转移给胎儿。",8.703288316726685,8.708807706832886,0.026117801666259766,0.6397793292999268,8.677170515060425,8.069028377532959,claude-sonnet-4-5-20250929,True
唑来膦酸注射液的潜在肾脏副作用有哪些？,chinese,What are the potential renal side effects of Zoledronic Acid Injection?,". Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, ACE-inhibitors, and angiotensin II receptor antagonists, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. A pharmacokinetic study in patients with mild and moderate renal impairment revealed that no dosage adjustments in these patient populations are required. Patients with severe renal impairment have not been studied

. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, ACE-inhibitors, and angiotensin II receptor antagonists, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. A pharmacokinetic study in patients with mild and moderate renal impairment revealed that no dosage adjustments in these patient populations are required. Patients with severe renal impairment have not been studied

. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Renal pelvic transitional epithelial hyperplasia, a spontaneous change occurring with variable frequency, was observed with increased frequency in treated male rats in a 2-year chronic study. Caution is recommended in patients with pre-existing kidney disease

. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Renal pelvic transitional epithelial hyperplasia, a spontaneous change occurring with variable frequency, was observed with increased frequency in treated male rats in a 2-year chronic study. Caution is recommended in patients with pre-existing kidney disease

. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Renal pelvic transitional epithelial hyperplasia, a spontaneous change occurring with variable frequency, was observed with increased frequency in treated male rats in a 2-year chronic study. Caution is recommended in patients with pre-existing kidney disease",". The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [ see Warnings and Precautions ( 5 ) and Dosage and Administration ( 2 ) ]. The most frequently observed adverse events were fever, nausea, constipation, anemia and dyspnea. (see Table 3 ). Table 3 provides adverse events that were reported by 10% or more of the 189 patients treated with Zoledronic Acid Injection 4 mg or Pamidronate 90 mg from the two HCM trials. Adverse events are listed regardless of presumed causality to study drug. Table 3: Percentage of Patients with Adverse Events ≥10% Reported in Hypercalcemia of Malignancy Clinical Trials by Body System Zoledronic Acid Injection 4 mg n (%) Pamidronate 90 mg n (%) Patients Studied Total No. of Patients Studied 86 (100) 103 (100) Total No

. The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [ see Warnings and Precautions ( 5 ) and Dosage and Administration ( 2 ) ]. The most frequently observed adverse events were fever, nausea, constipation, anemia and dyspnea. (see Table 3 ). Table 3 provides adverse events that were reported by 10% or more of the 189 patients treated with Zoledronic Acid Injection 4 mg or Pamidronate 90 mg from the two HCM trials. Adverse events are listed regardless of presumed causality to study drug. Table 3: Percentage of Patients with Adverse Events ≥10% Reported in Hypercalcemia of Malignancy Clinical Trials by Body System Zoledronic Acid Injection 4 mg n (%) Pamidronate 90 mg n (%) Patients Studied Total No. of Patients Studied 86 (100) 103 (100) Total No

. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients with Treatment Emergent Renal Function Deterioration by Baseline Serum Creatinine* *Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of Zoledronic Acid Injection to 15 minutes

. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients with Treatment Emergent Renal Function Deterioration by Baseline Serum Creatinine* *Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of Zoledronic Acid Injection to 15 minutes

. In the trials and in postmarketing experience, renal deterioration, progression to renal failure and dialysis have occurred in patients with normal and abnormal baseline renal function, including patients treated with 4 mg infused over a 15 - minute period. There have been instances of this occurring after the initial Zoledronic Acid Injection dose. 6.2 Postmarketing Experience The following adverse reactions have been reported during postapproval use of Zoledronic Acid Injection. Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Osteonecrosis of the Jaw Cases of osteonecrosis (primarily involving the jaws) have been reported predominantly in cancer patients treated with intravenous bisphosphonates including Zoledronic Acid Injection","Based on the medical information provided, I would like to clarify that: **The content provided primarily relates to the renal toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs), not the information about zoledronic acid injection. **

However, from the English content provided, we can learn that kidney side effects related to NSAIDs include:

## Mechanism of renal toxicity of NSAIDs:
- **Reduced prostaglandin synthesis**: dose dependent
- **Reduced renal blood flow**: secondary to reduced prostaglandin formation
- **May cause significant renal decompensation**

## High-risk groups:
- Patients with impaired renal function
- Heart failure patients
- Patients with liver dysfunction
- Patients taking diuretics
- Patients taking ACE inhibitors and angiotensin II receptor antagonists
- Seniors

## IMPORTANT NOTE:
- Recovery to pre-treatment status is usually possible after discontinuation of NSAID therapy
- No dose adjustment is required in patients with mild and moderate renal impairment
- Not studied in patients with severe renal impairment

**For information on specific renal side effects of Zoledronic Acid Injection, it is recommended to consult the specific instructions for the drug or consult a medical professional. **","Based on the provided medical information, the potential renal side effects of Zoledronic Acid Injection include:

## Primary Renal Side Effects:

1. **Renal toxicity** - The incidence can be reduced when the medication is administered as a 15-minute intravenous infusion

2. **Renal failure** - Similarly reduced with proper 15-minute infusion administration

3. **Renal deterioration** - Can occur in patients with both normal and abnormal baseline renal function

4. **Progression to renal failure requiring dialysis** - Has been documented in clinical trials and postmarketing experience

## Important Clinical Notes:

- These renal complications have occurred even when the drug was administered correctly (4 mg infused over 15 minutes)
- Renal problems can occur **after the initial dose**
- The risk affects patients regardless of their baseline kidney function (both those with normal and abnormal renal function at baseline)
- The 15-minute infusion duration is critical for reducing the incidence of these renal complications

The documentation emphasizes that proper administration (infusion over no less than 15 minutes) is essential to minimize renal toxicity risk, though it does not eliminate the possibility of renal complications entirely.",". Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-in
---
. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-in
---
. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-in
---
. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-in
---
. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-in",". The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be
---
. The incidence of renal toxicity and renal failure has been shown to be reduced when Zoledronic Acid Injection 4 mg is given as a 15 - minute intravenous infusion. Zoledronic Acid Injection should be
---
. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients wi
---
. The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see Table 9 ). Table 9: Percentage of Patients wi
---
. In the trials and in postmarketing experience, renal deterioration, progression to renal failure and dialysis have occurred in patients with normal and abnormal baseline renal function, including pa",Healthcare assistant prompt,"根据提供的医疗信息，我需要说明的是：**所提供的内容主要涉及非甾体抗炎药(NSAIDs)的肾脏毒性，而不是唑来膦酸注射液的信息。**

不过，从提供的英文内容中可以了解到NSAIDs相关的肾脏副作用包括：

## NSAIDs的肾脏毒性机制：
- **前列腺素合成减少**：呈剂量依赖性
- **肾血流量减少**：继发于前列腺素形成减少
- **可能导致明显的肾功能失代偿**

## 高危人群：
- 肾功能受损患者
- 心力衰竭患者
- 肝功能障碍患者
- 正在服用利尿剂的患者
- 正在服用ACE抑制剂和血管紧张素II受体拮抗剂的患者
- 老年人

## 重要提示：
- 停用NSAID治疗后通常可恢复到治疗前状态
- 轻度和中度肾功能不全患者无需调整剂量
- 严重肾功能不全患者尚未进行研究

**如需了解唑来膦酸注射液的具体肾脏副作用信息，建议查阅该药物的专门说明书或咨询医疗专业人员。**","根据所提供的医疗信息，唑来膦酸注射液的潜在肾脏副作用包括：

## 主要肾脏副作用：

1. **肾毒性** - 静脉输注15分钟可降低发生率

2. **肾衰竭** - 通过适当的 15 分钟输注给药同样可以减少

3. **肾功能恶化** - 基线肾功能正常和异常的患者均可发生

4. **进展为需要透析的肾衰竭** - 已在临床试验和上市后经验中记录

## 重要的临床注意事项：

- 即使正确给药（15 分钟内输注 4 毫克），也会发生这些肾脏并发症
- **初始剂量后**可能会出现肾脏问题
- 无论患者的基线肾功能如何（基线肾功能正常和异常的患者），该风险都会影响患者
- 15 分钟的输注时间对于降低这些肾脏并发症的发生率至关重要

该文件强调，正确的给药（输注不少于 15 分钟）对于最大限度地降低肾毒性风险至关重要，尽管它并不能完全消除肾脏并发症的可能性。",10.681014060974121,9.455803871154785,0.041175127029418945,0.42040586471557617,10.639838933944702,9.035398006439209,claude-sonnet-4-5-20250929,True
在唑来膦酸注射液的上市后使用中报告了哪些不良反应？,chinese,What adverse reactions have been reported during post-marketing use of zoledronic acid injection?,"ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Bone marrow failure, anemia, aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia. Hemolysis reported in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Cardiac disorders: Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see WARNINGS and OVERDOSAGE ). Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsade de pointes have been reported in patients taking Hydroxychloroquine sulfate tablets (see OVERDOSAGE and DRUG INTERACTIONS )

. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of indomethacin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and Appendages: Exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and fixed drug eruption (FDE).

. Laboratory Tests: Mild to moderate elevations of ALT, LDH, alkaline phosphatase, BUN and creatinine have been noted. The relationship of these abnormalities to glipizide is uncertain. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of glipizide extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure

. Metabolic acidosis has also been reported in patients receiving higher doses. Reports of extravasation with swelling have been received postmarketing. Rarely extravasation has been associated with necrosis and venous induration. The incidences of adverse reactions in the table that follows are derived from multiple databases from studies in 2,081 patients when Etoposide Injection USP was used either orally or by injection as a single agent. ADVERSE DRUG EFFECT PERCENT RANGE OF REPORTED INCIDENCE Hematologic toxicity Leukopenia (less than 1,000 WBC/mm 3 ) 3–17 Leukopenia (less than 4,000 WBC/mm 3 ) 60–91 Thrombocytopenia (less than 50,000 platelets/mm 3 ) 1–20 Thrombocytopenia (less than 100,000 platelets/mm 3 ) 22–41 Anemia 0–33 Gastrointestinal toxicity Nausea and vomiting 31–43 Abdominal pain 0–2 Anorexia 10–13 Diarrhea 1–13 Stomatitis 1–6 Hepatic 0–3 Alopecia 8–66 Peripheral neurotoxicity 1–2 Hypotension 1–2 Allergic reaction 1–2

. Henoch- Schonlein vasculitis, angioedema RENAL Acute renal failure (see PRECAUTIONS ), decreased creatinine clearance, polyuria, azotemia, cystitis, Hematuria Renal papillary necrosis MISCELLANEOUS Dry eyes and mouth, gingival ulcer, rhinitis Postmarketing Experience The following adverse reactions have been identified during postapproval use of ibuprofen. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin and Appendages: Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and fixed drug eruption (FDE).",". 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postmarketing use of gadobutrol injection or other GBCAs. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure

. 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postmarketing use of gadobutrol injection or other GBCAs. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure

. 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postmarketing use of gadobutrol injection or other GBCAs. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure

ADVERSE REACTIONS: ADVERSE REACTIONS Clinical Trials and Post-marketing Surveillance The adverse reactions listed below reflect the experience from investigational studies of Amnesteem, and the post-marketing experience. The relationship of some of these events to Amnesteem therapy is unknown. Many of the side effects and adverse reactions seen in patients receiving Amnesteem are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g., of the lips, nasal passage and eyes). Dose Relationship Cheilitis and hypertriglyceridemia are usually dose related. Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy (see WARNINGS and ADVERSE REACTIONS )

ADVERSE REACTIONS: ADVERSE REACTIONS Clinical Trials and Post-marketing Surveillance The adverse reactions listed below reflect the experience from investigational studies of Amnesteem, and the post-marketing experience. The relationship of some of these events to Amnesteem therapy is unknown. Many of the side effects and adverse reactions seen in patients receiving Amnesteem are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g., of the lips, nasal passage and eyes). Dose Relationship Cheilitis and hypertriglyceridemia are usually dose related. Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy (see WARNINGS and ADVERSE REACTIONS )","Based on the medical information provided, I found no post-marketing adverse reaction information about Zoledronic Acid Injection.

The documentation provided covers adverse reactions to the following drugs:
-Hydroxychloroquine sulfate tablets
- Indomethacin
- Glipizide extended-release tablets
- Etoposide Injection
- Ibuprofen

However, it does not include information about zoledronic acid injection. If you want to know the post-marketing adverse reactions of zoledronic acid injection, it is recommended to consult the special instructions for the drug or the FDA-approved drug label.","Based on the provided context, I cannot answer your question about zoledronic acid injection. The context only contains information about adverse reactions for:

1. Gadobutrol injection and other GBCAs (gadolinium-based contrast agents)
2. Amnesteem (isotretinoin)

There is no information about zoledronic acid injection in the provided materials. To get accurate information about post-marketing adverse reactions for zoledronic acid injection, you would need to consult the FDA prescribing information specifically for that medication.","ADVERSE REACTIONS: ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of Hydroxychloroquine sulfate tablets or other 4-aminoqunoline compounds. Because the
---
. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of indomethacin. Because these reactions are reported voluntarily from a population of uncer
---
. Laboratory Tests: Mild to moderate elevations of ALT, LDH, alkaline phosphatase, BUN and creatinine have been noted. The relationship of these abnormalities to glipizide is uncertain. 6.2 Postmarket
---
. Metabolic acidosis has also been reported in patients receiving higher doses. Reports of extravasation with swelling have been received postmarketing. Rarely extravasation has been associated with n
---
. Henoch- Schonlein vasculitis, angioedema RENAL Acute renal failure (see PRECAUTIONS ), decreased creatinine clearance, polyuria, azotemia, cystitis, Hematuria Renal papillary necrosis MISCELLANEOUS ",". 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postmarketing use of gadobutrol injection or other GBCAs. Because these reactions are reported vol
---
. 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postmarketing use of gadobutrol injection or other GBCAs. Because these reactions are reported vol
---
. 6.2 Postmarketing Experience The following additional adverse reactions have been identified during postmarketing use of gadobutrol injection or other GBCAs. Because these reactions are reported vol
---
ADVERSE REACTIONS: ADVERSE REACTIONS Clinical Trials and Post-marketing Surveillance The adverse reactions listed below reflect the experience from investigational studies of Amnesteem, and the post-m
---
ADVERSE REACTIONS: ADVERSE REACTIONS Clinical Trials and Post-marketing Surveillance The adverse reactions listed below reflect the experience from investigational studies of Amnesteem, and the post-m",Healthcare assistant prompt,"根据提供的医疗信息,我没有找到关于唑来膦酸注射液(Zoledronic Acid Injection)的上市后不良反应信息。

提供的文档内容涉及的是以下药物的不良反应:
- 羟氯喹硫酸盐片(Hydroxychloroquine sulfate tablets)
- 吲哚美辛(Indomethacin)
- 格列吡嗪缓释片(Glipizide extended-release tablets)
- 依托泊苷注射液(Etoposide Injection)
- 布洛芬(Ibuprofen)

但没有包含唑来膦酸注射液的相关信息。如需了解唑来膦酸注射液的上市后不良反应,建议查阅该药物的专门说明书或FDA批准的药品标签。","根据您提供的情况，我无法回答您有关唑来膦酸注射液的问题。上下文仅包含有关以下不良反应的信息：

1. 钆布醇注射液和其他GBCA（钆基造影剂）
2.Amnspect（异维A酸）

所提供的材料中没有关于唑来膦酸注射液的信息。要获得有关唑来膦酸注射液上市后不良反应的准确信息，您需要咨询 FDA 专门针对该药物的处方信息。",7.102780818939209,5.894445180892944,0.03446006774902344,0.49465107917785645,7.0683207511901855,5.399794101715088,claude-sonnet-4-5-20250929,True
